A catalog of associations between rare coding variants and COVID-19 outcomes

J. A. Kosmicki[1†], J. E. Horowitz[1†], N. Banerjee[1], R. Lanche[1], A. Marcketta[1], E. Maxwell[1], X. Bai[1],

D. Sun[1], J. D. Backman[1], D. Sharma[1], H. M. Kang[1], C. O'Dushlaine[1], A. Yadav[1], A. J. Mansfield[1],

A. H. Li[1], K. Watanabe[1], L. Gurski[1], S. E. McCarthy[1], A. E. Locke[1], S. Khalid[1], S. O'Keeffe[1], J.

Mbatchou[1], O. Chazara[2], Y. Huang[3], E. Kvikstad[5], A. O'Neill[2], P. Nioi[4], M. M. Parker[4], S.

Petrovski[2], H. Runz[3], J. D. Szustakowski[5], Q. Wang[2], E. Wong[6], A. Cordova-Palomera[6], E. N.

Smith[6], S. Szalma[6], X. Zheng[7], S. Esmaeeli[7], J. W. Davis[7], Y-P. Lai[8], X. Chen[8], A. E. Justice[9], J.

B. Leader[9], T. Mirshahi[9], D. J. Carey[9], A. Verma[10], G. Sirugo[10], M. D. Ritchie[10], D. J. Rader[10], G.

Povysil[11,12], D. B. Goldstein[11,12], K. Kiryluk[11,13], E. Pairo-Castineira[14,15], K. Rawlik[14], D. Pasko[16], S.

Walker[16], A. Meynert[15], A. Kousathanas[16], L. Moutsianas[16], A. Tenesa[14,15,17], M. Caulfield[16,18], R.

Scott[16,19], J. F. Wilson[15,17], J. K. Baillie[14,15,20], G. Butler-Laporte[21,22], T. Nakanishi[21,23-25], M.

Lathrop[23,26], J.B. Richards[21-23,27], Regeneron Genetics Center*, UKB Exome Sequencing

Consortium*, M. Jones[1], S. Balasubramanian[1], W. Salerno[1], A. R. Shuldiner[1], J. Marchini[1], J. D.

Overton[1], L. Habegger[1], M. N. Cantor[1], J. G. Reid[1], A. Baras[1‡], G. R. Abecasis[1‡], M. A. Ferreira[1‡]

From:

[1]Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA

[2]Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca,

Cambridge CB2 0AA, UK

[3]Biogen, 300 Binney St, Cambridge, MA 02142, USA

[4]Alnylam Pharmaceuticals, 675 West Kendall St, Cambridge, MA 02142, USA

[5]Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08543, USA

[6]Takeda California Inc., 9625 Towne Centre Dr, San Diego, CA 92121, USA

[7]AbbVie, Inc., 1 N. Waukegan Rd, North Chicago, IL 60064, USA

[8]Pfizer, Inc., 1 Portland Street, Cambridge MA 02139, USA

[9]Geisinger, Danville, PA, 17822, USA

[10]Department of Genetics, Perelman School of Medicine, University of Pennsylvania,

Philadelphia, PA, 19104, USA

[11]Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY

10032, USA

[12]Department of Genetics & Development, Columbia University, New York, NY 10032, USA

[13]Division of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons,

Columbia University, New York, NY 10032, USA

[14]Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK

[15]MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of

Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK

[16]Genomics England, London EC1M 6BQ, UK

[17]Centre for Global Health Research, Usher Institute of Population Health Sciences and

Informatics, Teviot Place, Edinburgh EH8 9AG, UK

[18]William Harvey Research Institute, Barts and the London School of Medicine and Dentistry,

Queen Mary University of London, London EC1M 6BQ, UK

[19]Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK

[20]Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16

5SA, UK

[21]Lady Davis Institute, Jewish General Hospital, Montréal, Québec H3T 1E2, Canada

[22]Department of Epidemiology, Biostatistics and Occupational Health, McGill University,

Montréal, Québec H3A 0G4, Canada

[23]Department of Human Genetics, McGill University, Montréal, Québec H3A 0G4, Canada

[24]Kyoto-McGill International Collaborative School in Genomic Medicine, Graduate School of

Medicine, Kyoto University, Kyoto 606-8501, Japan

[25]Research Fellow, Japan Society for the Promotion of Science

[26]Canadian Centre for Computational Genomics, McGill University, Montréal, Québec H3A

0G4, Canada

[27]Department of Twins Research, King's College London, London WC2R 2LS, UK

*A complete list of investigators is provided in the Supplementary Appendix.

†J. A. Kosmicki and J. E. Horowitz contributed equally to this manuscript.

‡A. Baras, G. R. Abecasis and M. A. Ferreira jointly supervised this work.

Correspondence to: manuel.ferreira@regeneron.com and goncalo.abecasis@regeneron.com

This research has been conducted using the UK Biobank Resource (Project 26041)

ABSTRACT

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease-19 (COVID-19), a respiratory illness that can result in hospitalization or death. We investigated associations between rare genetic variants and seven COVID-19 outcomes in 543,213 individuals, including 8,248 with COVID-19. After accounting for multiple testing, we did not identify any clear associations with rare variants either exome-wide or when specifically focusing on (i) 14 interferon pathway genes in which rare deleterious variants have been reported in severe COVID-19 patients; (ii) 167 genes located in COVID-19 GWAS risk loci; or (iii) 32 additional genes of immunologic relevance and/or therapeutic potential. Our analyses indicate there are no significant associations with rare protein-coding variants with detectable effect sizes at our current sample sizes. Analyses will be updated as additional data become available, with results publicly browsable at https://rgc-covid19.regeneron.com.

MAIN TEXT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] causes coronavirus

disease 2019 (COVID-19) [2]. COVID-19 ranges in clinical presentation from asymptomatic

infection to flu-like illness with respiratory failure, hyperactive immune responses and death [3-

5]. It is currently estimated that SARS-CoV-2 has infected >100 million individuals and has been

attributed to >2 million recorded deaths worldwide. Known risk factors for severe disease include

male sex, older age, ancestry, obesity and underlying cardiovascular, renal, and respiratory

diseases [6-9], among others.

Since the start of the SARS-CoV-2 pandemic, host genetic analysis of common genetic variation

among SARS-CoV-2 patients have identified at least nine genome-wide significant loci that

modulate COVID-19 susceptibility and severity, including variants in/near *LZTFL1*, *IFNAR2*,

DPP9 and the *HLA* region [10-13]. However, to date, there has been no assessment of the

contribution of rare genetic variation to COVID-19 disease susceptibility or severity through large

population-based exome-wide association analyses.

To identify rare variants (RVs, minor allele frequency [MAF]<1%) associated with COVID-19

susceptibility and severity, we generated exome-wide sequencing data for 543,213 individuals

from three studies (Geisinger Health System [GHS], Penn Medicine BioBank [PMBB] and UK

Biobank [UKB]) and three ancestries (African, European and South Asian) (**Supplementary**

Table 1). Of these, 8,248 had COVID-19, and among those 2,085 (25.28%) were hospitalized and

590 (7.15%) had severe disease (i.e. requiring ventilation or resulting in death; **Supplementary**

Table 2). Using these data, we tested the association between RVs and seven COVID-19

outcomes: five related to disease susceptibility and two related to disease severity among COVID-

19 cases (**Supplementary Table 3**). In a separate paper [13], we used these same phenotypes to

validate the association with common risk variants reported in previous COVID-19 GWAS[10-

12], thus demonstrating that our phenotypes are calibrated with those used in other studies.

For each phenotype, exome-wide association analyses were performed separately in each study

and ancestry using REGENIE[14], testing single RVs (~7 million) and a burden of RVs in 18,886

protein-coding genes. The genomic inflation factor (λ_{GC}) for RVs was often <1 in individual

studies, caused by a large proportion of variants having a minor allele count (MAC) of 0 in cases

(**Supplementary Table 4**). In meta-analyses across studies and ancestries, we found no RV

associations at a conservative $P<9.6 \times 10^{-10}$, which corresponds to a Bonferroni correction for the

number of variants and traits tested. The most significant associations with RVs are listed in **Table**

1, all observed with our COVID-19 hospitalization phenotype (2,085 hospitalized cases vs.

534,965 COVID-19 negative or unknown controls). Of these, we highlight an association with an

RV in the promoter of *EEF2* (rs532051930:A, MAF=0.003%, OR=93.9, 95% CI 20.3-434.5,

$P=6.2 \times 10^{-9}$; **Supplementary Figure 1A**), a translation elongation factor which plays a key role in

viral replication[15, 16].

Despite not reaching our threshold for genome-wide significance, we highlight the association

with *EEF2* because: (i) it was supported by two independent studies (**Supplementary Figure 1B**);

(ii) five additional RVs in the 89 bp promoter of *EEF2* (out of 50 tested) had an independent and

directionally-consistent predisposing association with the same hospitalization phenotype

($P<0.05$; **Supplementary Table 5**); (iii) rs532051930 is predicted by DeepSEA [17] to be a

regulatory variant and to disrupt binding of several transcription factors, including GABP, which

has been linked to RV-induced aberrant gene expression [18]; (iv) rs532051930 is located at the

peak of the transcription initiation region for *EEF2* (**Supplementary Figure 1C**) [19], suggesting

that it might affect RNA polymerase II binding; and (v) among a subset of 1,988 individuals with

available RNA-seq data from liver tissue, the only individual who was a carrier for rs532051930:A

had the second highest expression of *EEF2* (**Supplementary Figure 1D**). These results raise the

possibility that rs532051930 and potentially other promoter RVs increase *EEF2* transcription and,

consequently, increase risk of hospitalization due to SARS-CoV-2 infection.

Given these supporting observations and the established role of *EEF2* in viral replication, we

studied the genetic association with rs532051930 in greater detail, to understand if it was likely to

be a true-positive association. First, we reviewed sequencing reads for all 26 carriers of this variant,

to visually validate the heterozygote genotype call produced by the calling algorithm. Sequencing

reads were consistent with a heterozygote call for all 26 individuals. Second, we determined if the

association with this rare variant was robust to the association test used (**Supplementary Table**

6). A Firth test applied to a joint analysis of data across the two studies, adjusting for study specific

covariates as an offset, resulted in P=5.5x10^{-8}. Similar results were obtained by: (i) an

approximation to this approach, which combines log-likelihood curves calculated at a grid of

values with the Firth penalty, applied using approximate derivatives; (ii) a *P*-value-based meta-

analysis, for which there is evidence of better type-I error control [20]; and (iii) the BinomiRare

test [21], which uses a test statistic based on allele counts in cases only, adjusts for covariates and

combines data across studies. We also applied tests without covariates and these uniformly led to

less significant associations, but this is expected since the covariates explain variation in the

phenotype. Third, we attempted to replicate this association by querying whether this variant was

present in an additional 4,341 COVID-19 cases with exome- or whole-genome sequence data

generated as part of the GenOMICC (n=2,969) [11], Columbia University COVID-19 Biobank

(n=1,152) and Biobanque Quebec (n=220) [22] studies. We found no carriers for this variant in

these additional COVID-19 cases (**Supplementary Table 7**). Given these findings, we conclude

that it is not certain that there is a true association between rs532051930 and COVID-19 risk,

illustrating the importance of replication.

Next, we addressed the possibility that associations with protein-coding RVs might help pinpoint

target genes of common risk variants identified in GWAS of COVID-19. To this end, we focused

on 167 genes located within 500 kb of the nine common variants associated with COVID-19

hospitalization in a separate analysis [13]. Of the 334 gene burden tests performed (167 genes x 2

burden tests), which considered both pLoF variants alone (M1 burden test) or pLoF plus

deleterious missense variants (M3 burden test), 17 had a nominally significant association with the

same COVID-19 hospitalization phenotype (**Supplementary Table 6**). Of these, burden tests for

one gene – *CHAF1A* (OR=25 for the M1 burden test, 95% CI 4.9-128.5, $P=1.0\times10^{-4}$) – remained

borderline significant after correcting for the 334 tests performed ($P<0.05/334=1.5\times10^{-4}$).

CHAF1A is located 317 kb from the lead common variant at locus 19p13.3 [13], is highly

expressed in EBV-transformed B-cells [23] and encodes a component of the chromatin assembling

factor complex that affects cell differentiation, including the differentiation of pre-B cells into B-

cells and macrophages [24].

We then examined the association with 14 genes in the interferon pathway, given recent reports

that deleterious RVs in these genes may be implicated in severe clinical outcomes [25, 26]. Given

the larger sample size in our studies, we examined whether there was any evidence for association

between the COVID-19 hospitalization phenotype (2,085 cases vs. 534,965 controls) and the

burden of rare (MAF<0.1%) pLoF variants (M1 burden test) or pLoF plus deleterious missense

variants (M3 burden test) in these 14 genes, three of which are located within 500 kb of a COVID-

19 GWAS risk variant (*IFNAR1*, *IFNAR2* and *TICAM1*). Of the 14 genes, only two genes had a

nominal significant association: *STAT2* and *TLR7* (**Table 2**). However, neither remained

significant after correcting for the 28 tests performed (both with $P>0.05/28=0.0018$). Further, these

results were unchanged when testing COVID-19 severe cases (N=590), or when restricting the

burden tests to include variants with a MAF<1% or singleton variants (**Supplementary Table 7**).

Therefore, as recently reported by others [22], we found no evidence for an association between

RVs in these 14 interferon signaling genes and risk of COVID-19.

Lastly, we performed the same analysis for an additional 32 genes that are involved in the etiology

of SARS-CoV-2 infection (*ACE2, TMPRSS2*), encode therapeutic targets for COVID-19 obtained

through ClinicalTrials.gov (*e.g. IL6R, JAK1*) or have been implicated in other immune or

infectious diseases through GWAS (*e.g. IL33*). After correcting for multiple testing, there were

also no significant associations with a burden of deleterious RVs for this group of COVID-19

therapeutic target genes (**Supplementary Table 8**).

In summary, we provide a catalog of RV associations with COVID-19 outcomes based on exome-

sequence data, capturing genetic variation not assayed by array genotyping or imputation. We did

not find any convincing associations with current sample sizes, but will continue to expand our

analyses and update results periodically at https://rgc-covid19.regeneron.com.

METHODS

Participating Studies

Geisinger Health System (GHS). The GHS MyCode Community Health Initiative study has been described previously [27]. Briefly, the GHS study is a health system-based cohort from central and eastern Pennsylvania (USA) with ongoing recruitment since 2006. A subset of 144,182 MyCode participants sequenced as part of the GHS-Regeneron Genetics Center DiscovEHR partnership were included in this study. Information on COVID-19 outcomes were obtained through GHS's COVID-19 registry. Patients were identified as eligible for the registry based on relevant lab results and ICD-10 diagnosis codes; patient charts were then reviewed to confirm COVID-19 diagnoses. The registry contains data on outcomes, comorbidities, medications, supplemental oxygen use and ICU admissions.

Penn Medicine BioBank (PMBB) study. PMBB study participants are recruited through the University of Pennsylvania Health System, which enrolls participants during hospital or clinic visits. Participants donate blood or tissue and allow access to EHR information[28]. The PMBB COVID-19 registry consists of patients who have positive qPCR testing for SARS-COV-2. We then used electronic health records to classify COVID-19 patients into hospitalized and severe (ventilation or death) categories.

UK Biobank (UKB) study. We studied the host genetics of SARS-CoV-2 infection in participants of the UK Biobank study, which took place between 2006 and 2010 and includes approximately 500,000 adults aged 40-69 at recruitment. In collaboration with UK health authorities, the UK

Biobank has made available regular updates on COVID-19 status for all participants, including

results from four main data types: qPCR test for SARS-CoV-2, anonymized electronic health

records, primary care and death registry data. We report results based on the 12 September 2020

data refresh and excluded from the analysis 28,547 individuals with a death registry event prior to

2020.

COVID-19 phenotypes used for genetic association analyses

We grouped participants from each study into three broad COVID-19 disease categories

(**Supplementary Table 2**): (i) positive – those with a positive qPCR or serology test for SARS-

CoV-2, or a COVID-19-related ICD10 code (U07), hospitalization or death; (ii) negative – those

with only negative qPCR or serology test results for SARS-CoV-2 and no COVID-19-related

ICD10 code (U07), hospitalization or death; and (iii) unknown – those with no qPCR or serology

test results and no COVID-19-related ICD10 code (U07), hospitalization or death. We then used

these broad COVID-19 disease categories, in addition to hospitalization and disease severity

information, to create seven COVID-19-related phenotypes for genetic association analyses, as

detailed in **Supplementary Table 3**.

Array genotyping

Genotyping was performed on one of four SNP array types: Illumina OmniExpress Exome array

(OMNI; 59345 samples from GHS), Illumina Global Screening Array (GSA; PMBB and 82,527

samples from GHS), Applied Biosystems UK BiLEVE Axiom Array (49,950 samples from UKB),

or Applied Biosystems UK Biobank Axiom Array (438,427 samples from UKB). We retained

variants with a minor allele frequency (MAF) >1%, <10% missingness, Hardy-Weinberg

equilibrium test P-value>10^{-15}. Array data were then used: (i) to define ancestry subsets; and (ii)

to generate a polygenic risk score (PRS) predictor, as part of the exome-wide association analyses

carried out in REGENIE (see below).

Exome sequencing

Sample Preparation and Sequencing. Genomic DNA samples normalized to approximately 16

ng/ul were transferred to the Regeneron Genetics Center from the UK Biobank in 0.5ml 2D matrix

tubes (Thermo Fisher Scientific) and stored in an automated sample biobank (LiCONiC

Instruments) at -80°C prior to sample preparation. Exome capture was completed using a high-

throughput, fully-automated approach developed at the Regeneron Genetics Center. Briefly, DNA

libraries were created by enzymatically shearing 100ng of genomic DNA to a mean fragment size

of 200 base pairs using a custom NEBNext Ultra II FS DNA library prep kit (New England

Biolabs) and a common Y-shaped adapter (Integrated DNA Technologies [IDT]) was ligated to

all DNA libraries. Unique, asymmetric 10 base pair barcodes were added to the DNA fragment

during library amplification with KAPA HiFi polymerase (KAPA Biosystems) to facilitate

multiplexed exome capture and sequencing. Equal amounts of sample were pooled prior to

overnight exome capture, approximately 16 hours, with either (i) a slightly modified version of

IDT's xGen probe library (for UKB, PMBB and 81,620 samples of GHS); or (ii) NimbleGen

VCRome (58,856 samples of GHS). Captured fragments were bound to streptavidin-coupled

Dynabeads (Thermo Fisher Scientific) and non-specific DNA fragments removed through a series

of stringent washes using the xGen Hybridization and Wash kit according to the manufacturer's

recommended protocol (Integrated DNA Technologies). The captured DNA was PCR amplified

with KAPA HiFi and quantified by qPCR with a KAPA Library Quantification Kit (KAPA

Biosystems). The multiplexed samples were pooled and then sequenced using: (i) for UKB

samples – 75 bp paired-end reads with two 10 base pair index reads on the Illumina NovaSeq 6000

platform using S2 or S4 flow cells; (ii) for GHS samples captured with VCRome – 75 bp paired-

end reads with two 8 bp index reads on the Illumina HiSeq 2500; (iii) for GHS captured with IDT

– two 8 bp index reads on the Illumina HiSeq 2500 or two 10 bp index reads on the Illumina

NovaSeq 6000 on S4 flow cells; (iv) for UPENN-PMBB – two 10 bp index reads on the Illumina

NovaSeq 6000 on S4 flow cells.

Variant calling and quality control. Sample read mapping and variant calling, aggregation and

quality control were performed via the SPB protocol described in Van Hout et al. [29]. Briefly, for

each sample, NovaSeq WES reads are mapped with BWA MEM to the hg38 reference genome.

Small variants are identified with WeCall and reported as per-sample gVCFs. These gVCFs are

aggregated with GLnexus into a joint-genotyped, multi-sample VCF (pVCF). SNV genotypes with

read depth (DP) less than seven and indel genotypes with read depth less than ten are changed to

no-call genotypes. After the application of the DP genotype filter, a variant-level allele balance

filter is applied, retaining only variants that meet either of the following criteria: (i) at least one

homozygous variant carrier or (ii) at least one heterozygous variant carrier with an allele balance

(AB) greater than the cutoff (AB $\geq$ 0.15 for SNVs and AB $\geq$ 0.20 for indels).

Identification of low-quality variants from exome-sequencing using machine learning. Briefly, in

each study, we defined a set of positive control and negative control variants based on: (i)

concordance in genotype calls between array and exome sequencing data; (ii) Mendelian

inconsistencies in the exome sequencing data; (iii) differences in allele frequencies between exome

sequencing batches (UKB and GHS); (iv) variant loadings on 20 principal components derived

from the analysis of variants with a MAF<1%; (v) transmitted singletons. The model was then

trained on up to 30 available WeCall/GLnexus site quality metrics, including, for example, allele

balance and depth of coverage. We split the data into training (80%) and test (20%) sets. We

performed a grid search with 5-fold cross-validation on the training set to identify the

hyperparameters that return the highest accuracy during cross-validation, which are then applied

to the test set to confirm accuracy. This approach identified as low-quality a total of 7 million

variants in the UKB study (86% in the buffer region), 7.2 million across the two GHS datasets

(IDT and VCRome; 84% in the buffer region) and 1.1 million in the PMBB study (88% in the

buffer region). These variants were removed from analysis in the respective studies.

Gene burden masks. Briefly, for each gene region as defined by Ensembl [30], genotype

information from multiple rare coding variants was collapsed into a single burden genotype, such

that individuals who were: (i) homozygous reference (Ref) for all variants in that gene were

considered homozygous (RefRef); (ii) heterozygous for at least one variant in that gene were

considered heterozygous (RefAlt); (iii) and only individuals that carried two copies of the

alternative allele (Alt) of the same variant were considered homozygous for the alternative allele

(AltAlt). We did not phase rare variants; compound heterozygotes, if present, were considered

heterozygous (RefAlt). We did this separately for four classes of variants: (i) predicted loss of

function (pLoF), which we refer to as an "M1" burden mask; (ii) pLoF or missense ("M2"); (iii)

pLoF or missense variants predicted to be deleterious by 5/5 prediction algorithms ("M3"); (iv)

pLoF or missense variants predicted to be deleterious by 1/5 prediction algorithms ("M4").

Variants were annotated using SnpEff 4.3[31] and the most severe consequence for each variant

was chosen, considering complete protein-coding transcripts for each gene. The following variants

were considered to be pLoF variants: frameshift-causing indels, variants affecting splice acceptor

and donor sites, variants leading to stop gain, stop loss and start loss. The five missense deleterious

algorithms used were SIFT [32], PolyPhen2 (HDIV), PolyPhen2 (HVAR) [33], LRT [34], and

MutationTaster [35]. For each gene, and for each of these four groups, we considered five separate

burden masks, based on the frequency of the alternative allele of the variants that were screened

in that group: <1%, <0.1%, <0.01%, <0.001% and singletons only. Each burden mask was then

tested for association with the same approach used for individual variants (see below).

Genetic association analyses

Association analyses in each study were performed using the genome-wide Firth logistic

regression test implemented in REGENIE [14]. In this implementation, Firth's approach is applied

when the p-value from standard logistic regression score test is below 0.05. As the Firth penalty

(*i.e.* Jeffrey's invariant prior) corresponds to a data augmentation procedure where each

observation is split into a case and a control with different weights, it can handle variants with no

minor alleles among cases. With no covariates, this corresponds to adding 0.5 in every cell of a

2x2 table of allele counts versus case-control status.

We included in step 1 of REGENIE (*i.e.* prediction of individual trait values based on the

genetic data) array variants with a minor allele frequency (MAF) >1%, <10% missingness, Hardy-

Weinberg equilibrium test P-value>10^{-15} and linkage-disequilibrium (LD) pruning (1000 variant

windows, 100 variant sliding windows and r^2<0.9). The exception was the GHS study, for which

we used exome (not array) variants in step 1; we did this because two different exome capture

technologies (IDT and VCRome) were used to sequence the GHS samples, and so it was important

to capture in step 1 of REGENIE any differences in exome sequencing performance between IDT

and VCRome. We excluded from step 1 any SNPs with high inter-chromosomal LD, in the major

histo-compatibility (MHC) region, or in regions of low complexity.

The association model used in step 2 of REGENIE included as covariates (i) age, age^2, sex,

age-by-sex and age^2-by-sex; (ii) 10 ancestry-informative principle components (PCs) derived from

the analysis of a set of LD-pruned (50 variant windows, 5 variant sliding windows and $r^2<0.5$)

common variants from the array (imputed for the GHS study) data; (iii) an indicator for exome

sequencing batch (GHS: two IDT batches, one VCRome batch; UKB: six IDT batches); and (iv)

20 PCs derived from the analysis of exome variants with a MAF between $2.6x10^{-5}$ (roughly

corresponding to a minor allele count [MAC] of 20) and 1%. We corrected for PCs built from rare

variants because previous studies demonstrated PCs derived from common variants do not

adequately correct for fine-scale population structure [36, 37].

Within each study, association analyses were performed separately for five different

continental ancestries defined based on the array data: African (AFR), Admixed American (AMR),

European (EUR) and South Asian (SAS). We determined continental ancestries by projecting each

sample onto reference principle components calculated from the HapMap3 reference panel.

Briefly, we merged our samples with HapMap3 samples and kept only SNPs in common between

the two datasets. We further excluded SNPs with MAF<10%, genotype missingness >5% or

Hardy-Weinberg Equilibrium test p-value $< 10^{-5}$. We calculated PCs for the HapMap3 samples

and projected each of our samples onto those PCs. To assign a continental ancestry group to each

non-HapMap3 sample, we trained a kernel density estimator (KDE) using the HapMap3 PCs and

used the KDEs to calculate the likelihood of a given sample belonging to each of the five

continental ancestry groups. When the likelihood for a given ancestry group was >0.3, the sample

was assigned to that ancestry group. When two ancestry groups had a likelihood >0.3, we

arbitrarily assigned AFR over EUR, AMR over EUR, AMR over EAS, SAS over EUR, and AMR

over AFR. Samples were excluded from analysis if no ancestry likelihoods were >0.3, or if more

than three ancestry likelihoods were > 0.3.

Results were subsequently meta-analyzed across studies and ancestries using an inverse

variance-weighed fixed-effects meta-analysis.

Gene expression analysis in participants of the GHS study

For a subset of individuals from the GHS study (n=1,988, ascertained through the Geisinger

Bariatric Surgery Clinic), RNA was extracted from liver biopsies conducted during bariatric

surgery to evaluate liver disease. Individuals had class 3 obesity (BMI>40kg/m^2) or class 2 obesity

(BMI 35-39 kg/m^2) with an obesity-related co-morbidity (e.g. type-2 diabetes, hypertension, sleep

apnea, non-alcoholic fatty liver disease). RNA libraries were prepared using polyA-extraction and

then sequenced with 75bp paired-end reads with two 10 bp index reads on the Illumina NovaSeq

6000 on S4 flow cells. RNA-seq data were then analyzed using the GTEx v8 workflow[38], using

STAR [39] and RNASeqQC [40], except that GENCODE v32 was used in lieu of v26. Briefly: (i)

raw expression counts were normalized with TMM (Trimmed Mean of M-values) as implemented

in edgeR [40]; (ii) a rank-based inverse normal transformation was applied to the normalized

expression values; (iii) principal components (PCs) analysis was performed on data from 25,078

genes with TPM >0.1 in >20% samples, to identify latent factors accounting for variation in gene

expression; (iv) gene expression levels were adjusted for the top 100 PCs to improve power to

identify cis-regulatory effects.

Frequency of *EEF2* rare promoter variant in COVID-19 cases from independent studies

To help understand if the association between COVID-19 risk and rs532051930 in *EEF2* was likely to be a true-positive association, we determine its frequency in 4,341 cases from three additional studies.

GenOMICC (n=2,969). Individuals with severe COVID-19 were ascertained as described previously[11]. DNA samples were then whole-genome sequenced on the Illumina NovaSeq 6000 platform, aligned to the human reference genome hg38 and variant called to GVCF stage on the DRAGEN pipeline (software v01.011.269.3.2.22, hardware v01.011.269) at Genomics England. rs532051930 +/-50bp was genotyped with the GATK GenotypeGVCFs tool v4.1.8.1 and filtered to minimum depth 8X. Ancestry for individuals with array genotyping was inferred using ADMIXTURE[41] populations defined in 1000 Genomes[42]. When one individual had a probability > 80% of pertaining to one ancestry, then the individual was assigned to this ancestry, otherwise the individual was considered to be of admixed ancestry, as performed in the Million veteran program [43]. Somalier v0.2.12[44] was used to estimate ancestry for samples with whole-genome sequencing data. Predictions from Somalier were compared against predictions from ADMIXTURE for 1833 samples with both array genotyping and whole-genome sequencing data. Of these, the ancestry assignment matched between the two approaches for 1832 samples. Somalier predictions were used for the remaining 927 samples, of which 813 could be confidently (≥95% probability) assigned to a population; the remaining 114 were assigned to admixed ancestry.

Columbia University COVID-19 biobank (n=1,152). This cohort has previously been described in detail[22]. Briefly, 1,152 COVID-19 patients that were treated for COVID-19 at the Columbia University Irving Medical Center were recruited to the Columbia University COVID-

19 Biobank between March and May 2020. All patients had PCR-confirmed SARS-CoV-2

infection and the vast majority had severe COVID-19 requiring hospitalization. For all cases,

exomes were captured with the IDT xGen Exome Research Panel V1.0 and sequenced on

Illumina's NovaSeq 6000 platform with 150 bp paired-end reads according to standard protocols.

All cases were processed with the same bioinformatic pipeline for variant calling. In brief, reads

were aligned to human reference GRCh37 using DRAGEN and duplicates were marked with

Picard. Variants were called according to the Genome Analysis Toolkit (GATK) Best Practices

recommendations v3.66[45]. Finally, variants were annotated with ClinEff[31] and the IGM's in-

house tool ATAV[46]. A centralized database was used to store variant and per site coverage data

for all samples enabling well controlled analyses without the need of generating jointly called VCF

files (see Ren et al. 2020 for details[46]). For each patient, we performed ancestry classification

into one of the six major ancestry groups (European, African, Latinx, East Asian, South Asian and

Middle Eastern) using a neural network trained on a set of samples with known ancestry labels.

We used a 50% probability cut-off to assign an ancestry label to each sample and labeled samples

that did not reach 50% for any of the ancestral groups as "Admixed".

We only included samples that had at least 90% of the consensus coding sequence (CCDS

release 20[47]) covered at ≥ 10x and ≤ 3% contamination levels according to VerifyBamID[48].

Additionally, we removed samples with a discordance between self-declared and sequence-derived

gender and samples with an inferred relationship of second-degree or closer according to

KING[49]. All cases had at least 10x coverage at the position of rs532051930.

Biobanque Québec Covid-19 (n=220). The Biobanque Québec COVID-19

(www.BQC19.ca) is a provincial biobank prospectively enrolling patients with suspected COVID-

19, or COVID-19 confirmed through SARS-CoV-2 PCR testing and was previously described[22].

For this study, we used results from patients with available WGS data and who were recruited at

the Jewish General Hospital (JGH) in Montreal. The JGH is a university affiliated hospital serving

a large multi-ethnic adult population and the Québec government designated the JGH as the primary

COVID-19 reference center early in the pandemic. In total, Biobanque Quebec contained 533

participants with WGS, including 62 cases of COVID-19 who required invasive ventilatory support

(BiPAP, high flow oxygen, or endotracheal intubation) or died, 128 COVID-19 patients who were

hospitalized but did not require invasive ventilatory support, 30 individuals with COVID-19 did not

require hospitalization, and 313 SARS-CoV-2 PCR-negative participants. Using genetic PCAs

derived from genome-wide genotyping, 76% of participants were of European ancestry, 9% were

of African ancestry, 7% were of east Asian ancestry, and 5% were of south Asian ancestry.

We performed WGS at a mean depth of 30x on all individuals using Illumina's Novaseq

6000 platform (Illumina, San Diego, CA, USA). Sequencing results were analyzed using the

McGill Genome Center bioinformatics pipelines[50], in accordance with Genome Analysis

Toolkit (GATK) best practices recommendations[45]. Reads were aligned to the GRCh38

reference genome. Variant quality control was performed using the variantRecalibrator and

applyVQSR functions from GATK.

<u>Results availability</u>

All genotype-phenotype association results reported in this study are available for browsing using

the RGC's COVID-19 Results Browser (https://rgc-covid19.regeneron.com). Data access and use

is limited to research purposes in accordance with the Terms of Use (https://rgc-

covid19.regeneron.com/terms-of-use). The COVID-19 Results Browser provides a user-friendly

interface to explore genetic association results, enabling users to query summary statistics across

multiple cohorts and association studies using genes, variants or phenotypes of interest. Results

are displayed in an interactive tabular view ordered by p-value – enabling filtering, sorting,

grouping and viewing additional statistics – with link outs to individual GWAS reports, including

interactive Manhattan and QQ plots. LocusZoom views of LD information surrounding variants

of interest are also available, with LD calculated using the respective source genetic datasets.

The data resource supporting the COVID-19 Results Browser was built using a processed

version of the raw association analysis outputs. Using the RGC's data engineering toolkit based in

Apache Spark and Project Glow (https://projectglow.io/), association results were annotated,

enriched and partitioned into a distributed, columnar data store using Apache Parquet. Processed

Parquet files were registered with AWS Athena, which enables efficient, scalable queries on

unfiltered association result datasets. Additionally, "filtered" views of associations significant at a

threshold of p-value < 0.001 were stored in AWS RDS Aurora databases for low latency queries

to service primary views of top associations. APIs into RDS and Athena are managed behind the

scenes such that results with a p-value>0.001 are pulled from Athena as needed.

<u>Competing interests</u>

are employees and stockholders of Alnylam Pharmaceuticals. J.B.R. has served as an advisor to

GlaxoSmithKline and Deerfield Capital and these agencies had no role in the design,

implementation or interpretation of this study. S.S., E.W., A.C.P., and E.N.S. are employed by

Takeda. S.S. holds shares in Takeda and Janssen. The other authors declare no competing interests.

Acknowledgements

This research has been conducted using the UK Biobank Resource (Project 26041). The Penn

Medicine BioBank is funded by a gift from the Smilow family, the National Center for

Advancing Translational Sciences of the National Institutes of Health under CTSA Award

Number UL1TR001878, and the Perelman School of Medicine at the University of

Pennsylvania. Whole genome sequencing of the Biobanque Québec Covid-19 cohort was funded

by the CanCOGeN HostSeq project. The Richards research group is supported by the Canadian

Institutes of Health Research (CIHR), the Lady Davis Institute of the Jewish General Hospital,

the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK and the

Fonds de Recherche Québec Santé (FRQS). G.B.L. is supported by a joint research fellowship

from Quebec's ministry of health and social services, and the FRQS. T.N. is supported by

Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young Scientists

and JSPS Overseas Challenge Program for Young Researchers. J.B.R. is supported by a FRQS

Clinical Research Scholarship. The Columbia University Biobank was supported by Columbia

University and the National Center for Advancing Translational Sciences, NIH, through Grant

Number UL1TR001873. Columbia University COVID-19 Biobank members that additionally

contributed to this work include Muredach P. Reilly, Wendy Chung, Eldad Hod, Soumitra

Sengupta, Danielle Pendrick, Nitin Bhardwaj, Ning Shang, Atlas Khan, Chen Wang, Sheila M.

O'Byrne, Renu Nandakumar, Amritha Menon, Yat S. So, Richard Mayeux, Ali G. Gharavi,

Iuliana Ionita-Laza, Andrea Califano, Christine K. Garcia, Peter Sims, and Anne-Catrin

Uhlemann. The content is solely the responsibility of the authors and does not necessarily

represent the official views of the NIH or Columbia University. GenOMICC was funded by

Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome-Beit

Prize award to J. K. Baillie (Wellcome Trust 103258/Z/13/A), a BBSRC Institute Program

Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070 and

BBS/E/D/30002275), the Medical Research Council [grant MC_PC_19059]. Research

performed at the Human Genetics Unit was funded by the MRC (MC_UU_00007/10,

MC_UU_00007/15). Whole-genome sequencing was done in partnership with Genomics

England and was funded by UK Department of Health and Social Care, UKRI and LifeArc.

Genomics England and the 100,000 Genomes Project was funded by the National Institute for

Health Research, the Wellcome Trust, the Medical Research Council, Cancer Research UK, the

Department of Health and Social Care and NHS England. M Caulfield is an NIHR Senior

Investigator. This work is part of the portfolio of translational research at the NIHR Biomedical

Research Centre at Barts and Cambridge. LK was supported by an RCUK Innovation Fellowship

from the National Productivity Investment Fund (MR/R026408/1). We acknowledge support

from the MRC Human Genetics Unit programme grant, "Quantitative traits in health and

disease" (U. MC_UU_00007/10). A. Tenesa acknowledges funding from MRC research grant

MR/P015514/1, and HDR-UK award HDR-9004 and HDR-9003. Recruitment to GenOMICC

was enabled by the National Institute of Healthcare Research Clinical Research Network (NIHR

CRN) and the Chief Scientist Office (Scotland), who facilitate recruitment into research studies

in NHS hospitals, and to the global ISARIC and InFACT consortia. We thank the patients and

their loved ones who volunteered to contribute to this study at one of the most difficult times in

their lives, and the research staff in every intensive care unit who recruited patients at personal

risk during the most extreme conditions we have ever witnessed in UK hospitals.

Supplementary Figures

Supplementary Figure 1. Association between a rare promoter variant in EEF2

(rs532051930:A) and the COVID-19 hospitalization phenotype. (A) Regional association plot

centered on rs532051930. Orange triangles: individual rare variants (MAF<0.5%). Green squares:

burden tests. Grey circles: individual common variants (MAF>0.5%). **(B)** Forest plot showing

association in the two individual datasets included in the meta-analysis of this variant. **(C)** Results

from a population-scale PROcap (Precision Run-On 5' cap sequencing) study [19], which profiles

transcription start sites of nascent RNAs attached to RNA polymerase. The variant rs532051930

(vertical red line) is located 2 bp away from the peak of transcription initiation. (**D**) Distribution

of *EEF2* expression among 1,918 individuals from the GHS study with available RNA-seq data

from liver tissue. Vertical red line indicates expression levels for the only individual who was

heterozygote for the rare promoter variant rs532051930.

TABLES

Table 1. Top rare variant associations identified in this study ($P<10^{-8}$), all observed with the

phenotype COVID-19 positive and hospitalized (cases) vs. COVID-19 negative or unknown

(controls).

Variant	Effect allele	Odds Ratio [95% CI]	P-value	N cases with 0|1|2 copies of effect allele	N controls with 0|1|2 copies of effect allele	Effect allele frequency	Gene	Variant effect
rs374698271	T	81.60 [18.71,355.81]	4.65E-09	1698|5|0	399222|18|0	0.00003	*RFX2*	Intronic
rs532051930	A	93.90 [20.29,434.50]	6.17E-09	1869|4|0	508510|22|0	0.00003	*EEF2*	5 prime UTR
rs751932982	A	22.68 [7.89,65.23]	6.92E-09	1869|2|2	508247|44|8	0.00006	*FAM9B*	Intronic

Table 2. Association between the phenotype COVID-19 positive and hospitalized (cases) vs COVID-19 negative or unknown (controls) and 14 genes related to interferon signaling that were recently reported to contain rare (MAF<0.1%), deleterious variants in patients with severe COVID-19 [14, 23].

Variants included in burden test	Gene	Odds Ratio (95% CI)	P-value	N cases with RR|RA|AA genotype*	N controls with RR|RA|AA genotype*	AAF
pLoF, MAF<0.1%	IFNAR1	0.805[0.146;4.438]	8.00E-01	2019|1|0	525406|359|0	0.00034
	IFNAR2	2.077[0.620;6.961]	2.40E-01	2082|3|0	534277|688|0	0.00064
	IKBKG	0.491[0.005;50.219]	7.60E-01	1873|0|0	508491|31|10	0.00005
	IRF3	0.956[0.251;3.643]	9.50E-01	2083|2|0	534559|406|0	0.00038
	IRF7	1.165[0.426;3.185]	7.70E-01	2082|3|0	534124|841|0	0.00079
	IRF9	0.371[0.003;53.766]	7.00E-01	1873|0|0	508479|53|0	0.00005
	STAT1	0.365[0.001;126.712]	7.40E-01	1873|0|0	508490|42|0	0.00004
	STAT2	0.355[0.028;4.438]	4.20E-01	1873|0|0	508405|127|0	0.00012
	TBK1	0.365[0.011;11.964]	5.70E-01	1873|0|0	508445|87|0	0.00009
	TICAM1	3.730[0.189;73.610]	3.90E-01	1872|1|0	508368|164|0	0.00016
	TLR3	1.128[0.144;8.834]	9.10E-01	2084|1|0	534674|291|0	0.00027
	TLR7	7.627[1.872;31.075]	4.60E-03	1872|0|1	508503|25|4	0.00003
	TRAF3	0.368[0.000;733.638]	8.00E-01	1873|0|0	508504|28|0	0.00003
	UNC93B1	1.302[0.272;6.238]	7.40E-01	1938|2|0	516861|409|0	0.0004
pLoF or missense predicted deleterious, MAF<0.1%	IFNAR1	0.756[0.234;2.444]	6.40E-01	2083|2|0	534219|746|0	0.0007
	IFNAR2	1.968[0.598;6.469]	2.70E-01	2082|3|0	534253|712|0	0.00067
	IKBKG	0.446[0.010;19.737]	6.80E-01	1873|0|0	508452|70|10	0.00009
	IRF3	0.786[0.238;2.592]	6.90E-01	2083|2|0	534413|552|0	0.00052
	IRF7	1.137[0.519;2.492]	7.50E-01	2080|5|0	533486|1479|0	0.00138
	IRF9	0.371[0.003;53.766]	7.00E-01	1873|0|0	508479|53|0	0.00005
	STAT1	0.365[0.038;3.488]	3.80E-01	2018|0|0	526009|218|0	0.00021
	STAT2	2.600[1.272;5.314]	8.80E-03	2073|12|0	533405|1559|1	0.00146
	TBK1	1.114[0.445;2.790]	8.20E-01	2081|4|0	533861|1103|1	0.00103
	TICAM1	3.657[0.188;71.218]	3.90E-01	1872|1|0	508365|167|0	0.00016
	TLR3	0.805[0.435;1.493]	4.90E-01	2077|8|0	532355|2609|1	0.00244
	TLR7	1.580[0.627;3.979]	3.30E-01	2001|3|1	525830|477|163	0.00076
	TRAF3	3.013[0.527;17.217]	2.10E-01	2019|1|0	525523|242|0	0.00023
	UNC93B1	1.665[0.774;3.582]	1.90E-01	2075|10|0	533331|1634|0	0.00153

* RR: individuals who have genotype Reference/Reference for all variants included in burden test. RA: individuals who have genotype Reference/Alternate for at least one variant. AA: individuals who have genotype Alternate/Alternate for at least one variant.

540 **SUPPLEMENTARY TABLES**
541

Supplementary Tables 1 to 10 are provided in a separate document.

Supplementary Table 1. Demographics and clinical characteristics of study participants.

Supplementary Table 2. Breakdown of COVID-19 status across the four studies included in the

analysis.

Supplementary Table 3. Definitions used for the seven COVID-19 phenotypes analyzed.

Supplementary Table 4. Genomic inflation factor (λ_{GC}) observed in the analysis of exome

sequence variants for each of the eight phenotypes tested.

Supplementary Table 5. Association between the COVID-19 hospitalization phenotype and 50

rare variants in the promoter of *EEF2*.

Supplementary Table 6. Evidence for association between the COVID-19 hospitalization

phenotype and rs532051930 across different association tests.

Supplementary Table 7. No carriers of the rare variant rs532051930 in the promoter of EEF2

were observed in an additional 4,122 individuals with COVID-19.

Supplementary Table 8. Results from burden association tests for 167 genes located in eight loci

described in Horowitz et al. [13].

Supplementary Table 9. Results from burden association tests for 14 genes related to interferon

signaling and recently reported to contain rare (MAF<0.1%), deleterious variants in patients with

severe COVID-19.

Supplementary Table 10. Results from burden association tests for an additional 32 genes that

are involved in the etiology of SARS-CoV-2, encode therapeutic targets or have been implicated

in other immune or infectious diseases through GWAS.

References

1.   Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019.* New
England Journal of Medicine, 2020. **382**(8): p. 727-733.
2.   Coronaviridae Study Group of the International Committee on Taxonomy of, V., *The*
species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV
and naming it SARS-CoV-2. Nat Microbiol, 2020. **5**(4): p. 536-544.
3.   Guan, W.J., et al., *Clinical Characteristics of Coronavirus Disease 2019 in China.* N Engl J
Med, 2020. **382**(18): p. 1708-1720.
4.   Kimball, A., et al., *Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents*
of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020.
MMWR Morb Mortal Wkly Rep, 2020. **69**(13): p. 377-381.
5.   Bai, Y., et al., *Presumed Asymptomatic Carrier Transmission of COVID-19.* JAMA, 2020.
323(14): p. 1406-1407.
6.   Richardson, S., et al., *Presenting Characteristics, Comorbidities, and Outcomes Among*
5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama, 2020.
323(20): p. 2052-2059.
7.   Atkins, J.L., et al., *PREEXISTING COMORBIDITIES PREDICTING SEVERE COVID-19 IN OLDER*
ADULTS IN THE UK BIOBANK COMMUNITY COHORT. medRxiv, 2020: p.
2020.05.06.20092700.
8.   Zhou, F., et al., *Clinical course and risk factors for mortality of adult inpatients with*
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020. **395**(10229): p.
1054-1062.
9.   Cummings, M.J., et al., *Epidemiology, clinical course, and outcomes of critically ill adults*
with COVID-19 in New York City: a prospective cohort study. Lancet, 2020. **395**(10239):
p. 1763-1770.
10.   Shelton, J.F., et al., *Trans-ethnic analysis reveals genetic and non-genetic associations*
with COVID-19 susceptibility and severity. medRxiv, 2020: p. 2020.09.04.20188318.
11.   Pairo-Castineira, E., et al., *Genetic mechanisms of critical illness in Covid-19.* Nature,
2020.
12.   Ellinghaus, D., et al., *Genomewide Association Study of Severe Covid-19 with Respiratory*
Failure. New England Journal of Medicine, 2020.
13.   Horowitz, J.E., Kosmicki, J. A., et al. , *Common genetic variants identify therapeutic*
targets for COVID-19 and individuals at high risk of severe disease. medRxiv, 2020.
2020.12.14.20248176.
14.   Mbatchou, J., et al., *Computationally efficient whole genome regression for quantitative*
and binary traits. bioRxiv, 2020: p. 2020.06.19.162354.
15.   Valiente-Echeverria, F., et al., *eEF2 and Ras-GAP SH3 domain-binding protein (G3BP1)*
modulate stress granule assembly during HIV-1 infection. Nat Commun, 2014. **5**: p. 4819.
16.   Fernandez, I.S., et al., *Initiation of translation by cricket paralysis virus IRES requires its*
translocation in the ribosome. Cell, 2014. **157**(4): p. 823-31.
17.   Zhou, J. and O.G. Troyanskaya, *Predicting effects of noncoding variants with deep*
learning-based sequence model. Nat Methods, 2015. **12**(10): p. 931-4.

18.   Ferraro, N.M., et al., *Transcriptomic signatures across human tissues identify functional*
616   *rare genetic variation.* Science, 2020. **369**(6509).
617   19.   Kristjansdottir, K., et al., *Population-scale study of eRNA transcription reveals bipartite*
618   *functional enhancer architecture.* Nat Commun, 2020. **11**(1): p. 5963.
619   20.   Ma, C., et al., *Recommended joint and meta-analysis strategies for case-control*
620   *association testing of single low-count variants.* Genet Epidemiol, 2013. **37**(6): p. 539-50.
621   21.   Sofer, T., *BinomiRare: A robust test of the association of a rare variant with a disease for*
622   *pooled analysis and meta-analysis, with application to the HCHS/SOL.* Genet Epidemiol,
623   2017. **41**(5): p. 388-395.
624   22.   Povysil, G., et al., *Failure to replicate the association of rare loss-of-function variants in*
625   *type I IFN immunity genes with severe COVID-19.* medRxiv, 2020: p.
626   2020.12.18.20248226.
627   23.   Consortium, G.T., *The GTEx Consortium atlas of genetic regulatory effects across human*
628   *tissues.* Science, 2020. **369**(6509): p. 1318-1330.
629   24.   Cheloufi, S., et al., *The histone chaperone CAF-1 safeguards somatic cell identity.* Nature,
630   2015. **528**(7581): p. 218-24.
631   25.   van der Made, C.I., et al., *Presence of Genetic Variants Among Young Men With Severe*
632   *COVID-19.* JAMA, 2020.
633   26.   Zhang, S.Y., et al., *Severe COVID-19 in the young and healthy: monogenic inborn errors of*
634   *immunity?* Nat Rev Immunol, 2020. **20**(8): p. 455-456.
635   27.   Dewey, F.E., et al., *Distribution and clinical impact of functional variants in 50,726*
636   *whole-exome sequences from the DiscovEHR study.* Science, 2016. **354**(6319).
637   28.   Park, J., et al., *A genome-first approach to aggregating rare genetic variants in LMNA for*
638   *association with electronic health record phenotypes.* Genet Med, 2020. **22**(1): p. 102-
639   111.
640   29.   Van Hout, C.V., et al., *Exome sequencing and characterization of 49,960 individuals in*
641   *the UK Biobank.* Nature, 2020.
642   30.   Zerbino, D.R., et al., *Ensembl 2018.* Nucleic Acids Research, 2017. **46**(D1): p. D754-D761.
643   31.   Cingolani, P., et al., *A program for annotating and predicting the effects of single*
644   *nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster*
645   *strain w1118; iso-2; iso-3.* Fly (Austin), 2012. **6**(2): p. 80-92.
646   32.   Vaser, R., et al., *SIFT missense predictions for genomes.* Nat Protoc, 2016. **11**(1): p. 1-9.
647   33.   Adzhubei, I., D.M. Jordan, and S.R. Sunyaev, *Predicting functional effect of human*
648   *missense mutations using PolyPhen-2.* Curr Protoc Hum Genet, 2013. **7**(1): p. 7.20.1-
649   7.20.41.
650   34.   Chun, S. and J.C. Fay, *Identification of deleterious mutations within three human*
651   *genomes.* Genome research, 2009. **19**(9): p. 1553-1561.
652   35.   Schwarz, J.M., et al., *MutationTaster evaluates disease-causing potential of sequence*
653   *alterations.* Nat Methods, 2010. **7**(8): p. 575-6.
654   36.   Mathieson, I. and G. McVean, *Differential confounding of rare and common variants in*
655   *spatially structured populations.* Nature Genetics, 2012. **44**(3): p. 243-246.
656   37.   Zaidi, A.A. and I. Mathieson, *Demographic history impacts stratification in polygenic*
657   *scores.* bioRxiv, 2020: p. 2020.07.20.212530.

658   38.   Consortium, G.T., *The Genotype-Tissue Expression (GTEx) project.* Nat Genet, 2013.
659   **45**(6): p. 580-5.

660   39.   Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner.* Bioinformatics, 2013. **29**(1):
661   p. 15-21.

662   40.   Robinson, M.D. and A. Oshlack, *A scaling normalization method for differential*
663   *expression analysis of RNA-seq data.* Genome Biol, 2010. **11**(3): p. R25.

664   41.   Alexander, D.H. and K. Lange, *Enhancements to the ADMIXTURE algorithm for individual*
665   *ancestry estimation.* BMC Bioinformatics, 2011. **12**: p. 246.

666   42.   Auton, A., et al., *A global reference for human genetic variation.* Nature, 2015.
667   **526**(7571): p. 68-74.

668   43.   Gaziano, J.M., et al., *Million Veteran Program: A mega-biobank to study genetic*
669   *influences on health and disease.* J Clin Epidemiol, 2016. **70**: p. 214-23.

670   44.   Pedersen, B.S., et al., *Somalier: rapid relatedness estimation for cancer and germline*
671   *studies using efficient genome sketches.* Genome Med, 2020. **12**(1): p. 62.

672   45.   Van der Auwera, G.A., et al., *From FastQ data to high confidence variant calls: the*
673   *Genome Analysis Toolkit best practices pipeline.* Curr Protoc Bioinformatics, 2013.
674   **43**(1110): p. 11.10.1-11.10.33.

675   46.   Ren, Z., G. Povysil, and D.B. Goldstein, *ATAV: a comprehensive platform for population-*
676   *scale genomic analyses.* bioRxiv, 2020(p. 2020.06.08.136507.).

677   47.   Pruitt, K.D., et al., *The consensus coding sequence (CCDS) project: Identifying a common*
678   *protein-coding gene set for the human and mouse genomes.* Genome Res, 2009. **19**(7):
679   p. 1316-23.

680   48.   Jun, G., et al., *Detecting and estimating contamination of human DNA samples in*
681   *sequencing and array-based genotype data.* Am J Hum Genet, 2012. **91**(5): p. 839-48.

682   49.   Manichaikul, A., et al., *Robust relationship inference in genome-wide association studies.*
683   Bioinformatics, 2010. **26**(22): p. 2867-73.

684   50.   Bourgey, M., et al., *GenPipes: an open-source framework for distributed and scalable*
685   *genomic analyses.* Gigascience, 2019. **8**(6).

SUPPLEMENTARY TEXT

Regeneron Genetics Center (RGC) Research Team and Contribution Statements

All authors/contributors are listed in alphabetical order.

RGC Management and Leadership Team

Goncalo Abecasis, Ph.D., Aris Baras, M.D., Michael Cantor, M.D., Giovanni Coppola, M.D.,

Aris Economides, Ph.D., Luca A. Lotta, M.D., Ph.D., John D. Overton, Ph.D., Jeffrey G. Reid,

Ph.D., Alan Shuldiner, M.D.

Contribution: All authors contributed to securing funding, study design and oversight. All

authors reviewed the final version of the manuscript.

Sequencing and Lab Operations

Christina Beechert, Caitlin Forsythe, M.S., Erin D. Fuller, Zhenhua Gu, M.S., Michael Lattari,

Alexander Lopez, M.S., John D. Overton, Ph.D., Thomas D. Schleicher, M.S., Maria

Sotiropoulos Padilla, M.S., Louis Widom, Sarah E. Wolf, M.S., Manasi Pradhan, M.S., Kia

Manoochehri, Ricardo H. Ulloa.

Contribution: C.B., C.F., A.L., and J.D.O. performed and are responsible for sample genotyping.

C.B, C.F., E.D.F., M.L., M.S.P., L.W., S.E.W., A.L., and J.D.O. performed and are responsible

for exome sequencing. T.D.S., Z.G., A.L., and J.D.O. conceived and are responsible for

laboratory automation. M.P., K.M., R.U., and J.D.O are responsible for sample tracking and the

library information management system.

Clinical Informatics

Nilanjana Banerjee, Ph.D., Michael Cantor, M.D. M.A., Dadong Li, Ph.D., Deepika Sharma, MHI

Contribution: All authors contributed to the development and validation of clinical phenotypes used to identify study subjects and (when applicable) controls.

Genome Informatics

Xiaodong Bai, Ph.D., Suganthi Balasubramanian, Ph.D., Andrew Blumenfeld, Gisu Eom, Lukas Habegger, Ph.D., Alicia Hawes, B.S., Shareef Khalid, Jeffrey G. Reid, Ph.D., Evan K. Maxwell, Ph.D., William Salerno, Ph.D., Jeffrey C. Staples, Ph.D.

Contribution: X.B., A.H., W.S. and J.G.R. performed and are responsible for analysis needed to produce exome and genotype data. G.E. and J.G.R. provided compute infrastructure development and operational support. S.B., and J.G.R. provide variant and gene annotations and their functional interpretation of variants. E.M., J.S., A.B., L.H., J.G.R. conceived and are responsible for creating, developing, and deploying analysis platforms and computational methods for analyzing genomic data.

Analytical Genetics

Gonçalo R. Abecasis, Ph.D., Joshua Backman, Ph.D., Manuel A. Ferreira, Ph.D., Lauren Gurski, Jack A. Kosmicki, Ph.D., Alexander H. Li, Ph.D., Adam E. Locke, Ph.D., Anthony Marcketta, Jonathan Marchini, Ph.D., Joelle Mbatchou, Ph.D., Shane McCarthy, Ph.D., Colm O'Dushlaine, Ph.D., Dylan Sun, Kyoko Watanabe, Ph.D.

Contribution: J.A.K. and M.A.F. performed association analyses and led manuscript writing

group. J.B. identified low-quality variants in exome sequence data using machine learning. L.G.

and K.W. helped with visualization of association results. A.H.L., A.E.L., A.M. and D.S.

prepared the analytical pipelines to perform association analyses. J.M. and J.M. developed and

helped deploy REGENIE. S.M. and C.O'D. helped defined COVID-19 phenotypes. G.R.A.

supervised all analyses. All authors contributed to and reviewed the final version of the

manuscript.

Immune, Respiratory, and Infectious Disease Therapeutic Area Genetics

Julie E. Horowitz, PhD.

Contribution: J.E.H. helped defined COVID-19 phenotypes, interpret association results and led

the manuscript writing group.

Research Program Management

Marcus B. Jones, Ph.D., Michelle LeBlanc, Ph.D., Jason Mighty, Ph.D., Lyndon J. Mitnaul,

Ph.D.

Contribution: All authors contributed to the management and coordination of all research

activities, planning and execution. All authors contributed to the review process for the final

version of the manuscript.

UK Biobank Exome Sequencing Consortium Research Team

[1]Bristol Myers Squibb

Oleg Moiseyenko, Carlos Rios, Saurabh Saha

[2]Regeneron Pharmaceuticals Inc.

Listed in pages 38 to 40.

[3]Biogen Inc.

Sally John, Chia-Yen Chen, David Sexton, Paola G. Bronson, Christopher D. Whelan, Varant Kupelian, Eric Marshall, Timothy Swan, Susan Eaton, Jimmy Z. Liu, Stephanie Loomis, Megan Jensen, Saranya Duraisamy, Ellen A. Tsai, Heiko Runz

[4]Alnylam Pharmaceuticals

Aimee M. Deaton, Margaret M. Parker, Lucas D. Ward, Alexander O. Flynn-Carroll, Greg Hinkle, Paul Nioi

[5]AstraZeneca

Olympe Chazara, Sri VV. Deevi, Xiao Jiang, Amanda O'Neill, Slavé Petrovski, Katherine Smith, Quanli Wang

[6]Takeda California Inc

Jason Tetrault, Dorothee Diogo, Aldo Cordova Palomera, Emily Wong, Rajesh Mikkilineni,

David Merberg, Sunita Badola, Erin N. Smith, Sandor Szalma

[7]Pfizer, Inc

Yi-Pin Lai, Xing Chen, Xinli Hu, Melissa R. Miller

[8]Abbvie

Xiuwen Zheng, Bridget Riley-Gillis, Jason Grundstad, Sahar Esmaeeli, Jeff Waring, J. Wade

Davis

[1]Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08543, USA

[2]Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591,

USA

[3]Biogen Inc., 225 Binney Street, Cambridge, MA 02139, USA

[4]Alnylam Pharmaceuticals, 675 West Kendall St, Cambridge, MA 02142, USA

[5]AstraZeneca Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D,

Cambridge, UK

[6]Takeda California Inc., 9625 Towne Centre Dr, San Diego, CA 92121, USA

[7] Pfizer, Inc., 1 Portland Street, Cambridge MA 02139, USA

[8] AbbVie, Inc., 1 N. Waukegan Rd, North Chicago, IL 60064, USA

GenOMICC Consortium

Sara Clohisey[1], Fiona Griffiths[1], James Furniss[1], James Furniss[1], Trevor Paterson[1], Tony Wackett[1], Ruth Armstrong[1], Wilna Oosthuyzen[1], Nick Parkinson[1], Max Head Fourman[1], Andrew Law[1], Veronique Vitart[2], Lucija Klaric[2], Anne Richmond[2], Chris P. Ponting[2], Andrew D. Bretherick[2], Charles Hinds[3], Timothy Walsh[4], Sean Keating[4], Clark D Russell[1,5], Malcolm G. Semple[6,7], Kathy Rowan[8], Elvina Gountouna[9], Nicola Wrobel[10], Lee Murphy[10], Angie Fawkes[10], Richard Clark[10], Audrey Coutts[10], Lorna Donnelly[10], Tammy Gilchrist[10], Katarzyna Hafezi[10], Louise Macgillivray[10], Alan Maclean[10], Sarah McCafferty[10], Kirstie Morrice[10], , Angie Fawkes[10], Julian Knight[11], Charlotte Summers[12], Manu Shankar-Hari[13,14], Peter Horby[15], Alistair Nichol[16,17,18], David Maslove[19], Lowell Ling[20], Danny McAuley[21,22], Hugh Montgomery[23], Peter J.M. Openshaw[24,25].

[1]Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK

[2]MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK

[3]William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK

[4]Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK

[5]Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, UK

[6]NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, Liverpool, L69 7BE, UK

[7]Respiratory Medicine, Alder Hey Children's Hospital, Institute in The Park, University of Liverpool, Alder Hey Children's Hospital, Liverpool, UK

[8]Intensive Care National Audit & Research Centre, London, UK

[9]Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK

[10]Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh,

EH4 2XU, UK

[11]Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK

[12]Department of Medicine, University of Cambridge, Cambridge, UK

[13]Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust,

London, UK

[14]School of Immunology and Microbial Sciences, King's College London, UK

[15]Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University

of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK

[16]Clinical Research Centre at St Vincent's University Hospital, University College Dublin,

Dublin, Ireland

[17]Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne,

Australia

[18]Intensive Care Unit, Alfred Hospital, Melbourne, Australia

[19]Department of Critical Care Medicine, Queen's University and Kingston Health Sciences

Centre, Kingston, ON, Canada

[20]Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince

of Wales Hospital, Hong Kong, China

[21]Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast,

Northern Ireland, UK

[22]Department of Intensive Care Medicine, Royal Victoria Hospital, Belfast, Northern Ireland,

UK

[23]UCL Centre for Human Health and Performance, London, W1T 7HA, UK

[24]National Heart and Lung Institute, Imperial College London, London, UK

[25]Imperial College Healthcare NHS Trust: London, London, UK

SUPPLEMENTARY FIGURES

A.

rs532051930

B.

STUDY	N CASES RR|RA|AA	N CONTROLS RR|RA|AA	OR [95% CI]	PVALUE	AAF
UKB_Freeze_450_EUR	1700|3|0	399228|12|0	80.95 [13.12,499.469]	2.2e-06	2e-05
GHS_Freeze_145_EUR	169|1|0	109282|10|0	134.763 [7.892,2301.292]	7.1e-04	5e-05
META	**1869|4|0**	**508510|22|0**	**93.906 [20.295,434.505]**	**6.2e-09**	**3e-05**

C.

D.

Individual heterozygote for rs532051930:A

Supplementary Figure 1. **Association between a rare promoter variant in *EEF2* (rs532051930:A) and the COVID-19 hospitalization phenotype. (A)** Regional association plot centered on rs532051930. Orange triangles: individual rare variants (MAF<0.5%). Green squares: burden tests. Grey circles: individual common variants (MAF>0.5%). **(B)** Forest plot showing association in the two individual datasets included in the meta-analysis of this variant. **(C)** Results from a population-scale PROcap (Precision Run-On 5' cap sequencing) study [19], which profiles transcription start sites of nascent RNAs attached to RNA polymerase. The variant rs532051930 (vertical red line) is located 2 bp away from the peak of transcription initiation. **(D)** Distribution of *EEF2* expression among 1,918 individuals from the GHS study with available RNA-seq data from liver tissue. Vertical red line indicates expression levels for the only individual who was heterozygote for the rare promoter variant rs532051930.

SUPPLEMENTARY TABLES

Supplementary Table 1. Demographics and clinical characteristics of study participants.

Demographics	COVID-19 Positive		Covid-19 Negative or Unknown
	Hospitalized	**Not Hospitalized**	
UK Biobank			
Total N	1848	5400	416935
AFR ancestry, n (%)	80 (3.8)	134 (2.2)	8495 (1.8)
EUR ancestry, n (%)	1703 (81.9)	5030 (83.2)	399240 (85.7)
SAS ancestry, n (%)	65 (3.1)	236 (3.9)	9200 (1.9)
Average Age, y (% >60y)	59.7 (57)	52.6 (22)	56.2 (36)
Female, n (%)	737 (39.8)	2896 (53.6)	229572 (55.1)
Hypertension, n (%)	884 (47.8)	1214 (22.5)	96851 (23.2)
Cardiovascular Disease, n (%)	265 (14.3)	330 (6.1)	24859 (5.8)
Type 2 Diabetes, n (%)	342 (18.5)	378 (7)	25335 (6.1)
Chronic kidney disease, n (%)	134 (7.3)	112 (2.1)	8096 (1.9)
Asthma, n (%)	343 (18.5)	886 (16.4)	59229 (14.2)
COPD, n (%)	208 (11.2)	164 (3)	10117 (2.4)
GHS			
Total N	170	664	109292
EUR ancestry, n (%)	170 (100)	664 (100)	109292 (100)
Average Age, y (% >60y)	67.81 (76.47)	54.74 (39.0)	55.75 (44.14)
Female, n (%)	90 (52.94)	435 (65.51)	68226 (62.42)
Hypertension, n (%)	138 (81.17)	343 (51.65)	53658 (49.09)
Cardiovascular Disease, n (%)	77 (45.29)	108 (16.26)	17269 (15.80)
Type 2 Diabetes, n (%)	73 (42.94)	158 (23.79)	23290 (21.30)
Chronic kidney disease, n (%)	64 (37.64)	94 (14.15)	14246 (13.03)
Asthma, n (%)	15 (8.82)	47 (7.07)	6975 (6.38)
COPD, n (%)	47(27.64)	67 (10.09)	10822 (9.90)
PMBB			
Total N	67	99	959
AFR ancestry, n (%)	67 (100)	99 (100)	959 (100)
Average Age, y (% >60y)	62.58 (61.19)	47.64 (19.19)	56.24 (43.27)
Female, n (%)	38 (56.7)	72 (72.7)	641 (66.8)
Hypertension, n (%)	59 (88.1)	52 (52.5)	704 (73.4)
Cardiovascular Disease, n (%)	40 (59.7)	17 (17.2)	359 (37.4)
Type 2 Diabetes, n (%)	50 (74.6)	31 (31.3)	440 (45.9)
Chronic kidney disease, n (%)	42 (62.7)	13 (13.1)	300 (31.3)
Asthma, n (%)	18 (26.9)	23 (23.2)	294 (30.7)
COPD, n (%)	20 (29.9)	8 (8.1)	145 (15.1)

Supplementary Table 2. Breakdown of COVID-19 status across the four studies included in the analysis.

COVID-19 status	Positive qPCR or serology for SARS-CoV-2	ICD10 U07 diagnosis or hospitalization	Severe COVID-19 (ventilation or death)	Negative qPCR or serology test for SARS-CoV-2	UK Biobank	GHS	PMBB	Total
Positive	Yes	Yes	Yes	Yes or No or NA	382	49	27	458
	Yes	Yes	No or NA	Yes or No or NA	1119	121	40	1,280
	Yes	No or NA	Yes	Yes or No or NA	0	0	0	0
	Yes	No or NA	No or NA	Yes or No or NA	5400	664	99	6,163
	No or NA	Yes	Yes	No or NA	122	0	0	122
	No or NA	Yes	No or NA	No or NA	77	0	0	77
	No or NA	No or NA	Yes	No or NA	0	0	0	0
	No or NA	Yes	Yes	Yes	37	0	0	37
	No or NA	Yes	No or NA	Yes	111	0	0	111
	No or NA	No or NA	Yes	Yes	0	0	0	0
					Total = 7248	Total = 834	Total = 166	Total = 8248
Negative	No or NA	No or NA	No or NA	Yes	32,867	15,574	959	49,400
Unknown	NA	No or NA	No or NA	NA	384,068	93,718	7,779	485,565
Total					424,183	110,126	8,904	543,213

Supplementary Table 3. Definitions used for the seven COVID-19 phenotypes analyzed.

Broad phenotype category	Phenotype	Case/control group	Definition			Sample size with genetic data			
			COVID-19 status	Hospitalized	Severe disease	UK Biobank	GHS	PMBB	Total
Risk of infection	COVID-19 positive vs. COVID-19 negative or unknown	Cases	Positive	Yes, No or NA	Yes, No or NA	7,248	834	166	8,248
		Controls	Negative or unknown	No or NA	No or NA	416,935	109,292	8,738	534,965
	COVID-19 positive vs. COVID-19 negative	Cases	Positive	Yes, No or NA	Yes, No or NA	7,248	834	166	8,248
		Controls	Negative	No or NA	No or NA	32,867	15,574	959	49,400
	COVID-19 positive and not hospitalized vs. COVID-19 negative or unknown	Cases	Positive	No	No	5,400	664	99	6,163
		Controls	Negative or unknown	No or NA	No or NA	416,935	109,292	8,738	534,965
	COVID-19 positive and hospitalized vs. COVID-19 negative or unknown	Cases	Positive	Yes (or death)	Yes, No or NA	1,848	170	67	2,085
		Controls	Negative or unknown	No or NA	No or NA	416,935	109,292	8,738	534,965
	COVID-19 positive and severe vs. COVID-19 negative or unknown	Cases	Positive	Yes, No or NA	Yes	541	49	NA	590
		Controls	Negative or unknown	No or NA	No or NA	416,935	109,292	NA	526,227
Risk of adverse outcomes amongst infected individuals	COVID-19 positive and hospitalized vs. COVID-19 positive and not hospitalized	Cases	Positive	Yes (or death)	Yes, No or NA	1,703	170	67	1,940
		Controls	Positive	No	No	5,030	664	99	5,793
	COVID-19 positive and severe vs. COVID-19 positive and not hospitalized	Cases	Positive	Yes, No or NA	Yes	523	49	NA	572
		Controls	Positive	No	No	5,164	664	NA	5,828

Supplementary Table 4. Genomic inflation factor (lambda GC) observed in the analysis of exome sequence variants for each of the seven phenotypes tested.

Phenotype	Study	Ancestry	N cases	N controls	Exome-sequencing variants with MAF<0.5% & MAC>=5			Exome-sequencing variants with MAF<0.5% & MAC>25			Exome-sequencing variants with MAF>0.5%		
					N variants	Proportion of variants with MAC=0 in cases	Lambda GC	N variants	Proportion of variants with MAC=0 in cases	Lambda GC	N variants	Proportion of variants with MAC=0 in cases	Lambda GC
COVID19_positive_hospitalized_vs_COVID19_negative_or_unknown_combined	UKB Freeze 450	SAS	65	9200	798145	0.873	0.202	222553	0.719	0.774	227664	0.193	1.254
	UPENN-PMBB_Freeze_One	AFR	67	8738	890983	0.857	0.215	279379	0.708	0.748	486699	0.132	1.099
	UKB Freeze 450	AFR	80	8495	812651	0.830	0.268	248412	0.653	0.803	380222	0.120	0.947
	GHS Freeze 145 Exome	EUR	170	109292	2899753	0.933	0.042	889226	0.815	0.23	172227	0.046	0.997
	UKB Freeze 450	EUR	1703	399240	6411484	0.849	0.126	2074846	0.622	0.555	166323	0.000	1.004
	Meta-analysis	ALL	2085	534965	8053662	0.832	0.126	2833904	0.599	0.554	352116	0.043	1.02
COVID19_positive_hospitalized_vs_COVID19_positive_not_hospitalized_combined	UPENN-PMBB Freeze One	AFR	67	99	NA	NA	NA	NA	NA	NA	330315	0.012	0.183
	GHS Freeze 145 Exome	EUR	170	664	209299	0.549	0.866	NA	NA	NA	173449	0.035	1.079
	UKB Freeze 450	EUR	1703	5030	424564	0.072	1.099	112045	0.000	1.043	166403	0.000	1.037
	Meta-analysis	ALL	1940	5793	462977	0.126	1.017	128932	0.000	1.021	398264	0.009	0.388
COVID19_positive_not_hospitalized_vs_COVID19_negative_or_unknown_combined	UPENN-PMBB Freeze One	AFR	99	8738	893407	0.796	0.338	280294	0.596	0.992	487296	0.076	0.961
	UKB Freeze 450	AFR	134	8495	816964	0.736	0.48	250786	0.492	1.218	379423	0.050	0.998
	UKB Freeze 450	SAS	236	9200	808557	0.652	0.622	226850	0.325	1.326	227147	0.016	1.016
	GHS Freeze 145 Exome	EUR	664	109292	2907752	0.824	0.167	892254	0.559	0.731	172221	0.001	1.016
	UKB Freeze 450	EUR	5030	399240	6440585	0.722	0.345	2086994	0.387	1.074	166350	0.000	1.019
	Meta-analysis	ALL	6163	534965	8091286	0.710	0.345	2849393	0.385	1.059	351738	0.020	0.982
COVID19_positive_severe_vs_COVID19_negative_or_unknown_combined	UKB Freeze 450	SAS	18	9200	796240	0.961	0.04	222161	0.910	0.163	226990	0.496	0.749
	UKB Freeze 450	AFR	33	8495	811241	0.919	0.132	248076	0.831	0.346	379346	0.302	0.821
	GHS Freeze 145 Exome	EUR	49	109292	2895469	0.976	0.013	888545	0.932	0.08	172229	0.246	0.785
	UKB Freeze 450	EUR	490	399240	6400400	0.931	0.034	2070233	0.812	0.176	166321	0.001	1.02
	Meta-analysis	ALL	590	526227	7876462	0.917	0.037	2721522	0.783	0.214	225588	0.090	0.889
COVID19_positive_severe_vs_COVID19_positive_not_hospitalized_combined	UKB Freeze 450	AFR	33	134	NA	NA	NA	NA	NA	NA	235941	0.109	0.234
	GHS Freeze 145 Exome	EUR	49	664	194798	0.818	0.273	NA	NA	NA	170209	0.228	1.141
	UKB Freeze 450	EUR	490	5030	373269	0.327	1.078	87177	0.043	1.013	166184	0.001	0.998
	Meta-analysis	ALL	572	5828	410271	0.365	0.912	101899	0.035	0.968	301689	0.056	0.593
COVID19_positive_vs_COVID19_negative_combined	UPENN-PMBB Freeze One	AFR	166	959	195274	0.331	1.345	NA	NA	NA	484596	0.023	0.974
	UKB Freeze 450	AFR	214	766	141313	0.206	1.071	NA	NA	NA	387132	0.013	0.938
	UKB Freeze 450	SAS	301	844	149617	0.129	1.111	NA	NA	NA	228543	0.004	1.07
	GHS Freeze 145 Exome	EUR	834	15574	896282	0.505	0.889	239671	0.091	1.024	172248	0.000	1.019
	UKB Freeze 450	EUR	6733	31257	1361423	0.143	1.15	417941	0.001	1.015	166646	0.000	1
	Meta-analysis	ALL	8248	49400	1745716	0.203	1.023	575968	0.005	1.025	471978	0.006	0.984
COVID19_positive_vs_COVID19_negative_or_unknown_combined	UPENN-PMBB Freeze One	AFR	166	8738	897805	0.700	0.519	282679	0.434	1.219	486918	0.029	0.972
	UKB Freeze 450	AFR	214	8495	821371	0.636	0.666	253263	0.335	1.356	379070	0.015	1.02
	UKB Freeze 450	SAS	301	9200	812263	0.595	0.735	228572	0.246	1.267	226861	0.007	1.012
	GHS Freeze 145 Exome	EUR	834	109292	2910461	0.799	0.205	893247	0.509	0.844	172192	0.001	1.026
	UKB Freeze 450	EUR	6733	399240	6455895	0.675	0.446	2093385	0.315	1.175	166339	0.000	1.017
	Meta-analysis	ALL	8248	534965	8111082	0.663	0.443	2857926	0.315	1.161	351576	0.009	0.996

Supplementary Table 5. Association between the COVID-19 hospitalization phenotype and 50 rare variants in the promoter of EEF2.

rs ID	hg38	Effect allele	Odds Ratio	95% LCI	95% UCI	SE	P-value	Effect allele frequency	N cases with 0|1|2 copies of effect allele	N controls with 0|1|2 copies of effect allele	Studies analyzed
rs532051930	19:3985461:G:A	A	93.9065	20.2954	434.505	0.7816	6.18E-09	2.55E-05	1869|4|0	508510|22|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs374797871	19:3985414:A:G	G	24.2157	1.84809	317.299	1.3127	0.0152	0.000547	146|1|0	17215|18|0	UKB_Freeze_450_AFR UPENN-PMBB_Freeze_One_AFR Meta
rs754033543	19:3985383:T:C	C	18.9215	1.73245	206.658	1.2198	0.0159	0.000027	1702|1|0	399219|21|0	UKB_Freeze_450_EUR Meta
rs542049090	19:3985437:A:G	G	18.6529	1.72231	202.014	1.2155	0.0161	0.000026	1769|1|0	407947|20|0	UKB_Freeze_450_EUR UPENN-PMBB_Freeze_One_AFR Meta
rs897131413	19:3985457:G:C	C	17.7894	1.63807	193.191	1.2169	0.0180	0.000047	1872|1|0	508477|47|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs370100022	19:3985421:G:A	A	5.21063	1.10233	24.6302	0.7925	0.0373	0.000140	1936|2|0	517585|144|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR UKB_Freeze_450_SAS Meta
rs546488032	19:3985433:G:A	A	6.19102	0.776398	49.3674	1.0593	0.0852	0.000057	1937|1|0	517671|56|1	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR UKB_Freeze_450_SAS Meta
rs201347619	19:3985401:T:A	A	0.364401	0.0678296	1.95767	0.8578	0.2393	0.004028	147|0|0	17094|138|1	UKB_Freeze_450_AFR UPENN-PMBB_Freeze_One_AFR Meta
rs369523513	19:3985436:G:A	A	0.36233	0.0593301	2.21276	0.9232	0.2715	0.000116	2020|0|0	525596|120|1	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_AFR UKB_Freeze_450_EUR UPENN-PMBB_Freeze_One_AFR Meta
rs373888946	19:3985451:G:T	T	0.363709	0.0429819	3.07768	1.0896	0.3533	0.000204	1873|0|0	508319|208|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs907273439	19:3985443:G:C	C	2.35632	0.354027	15.6831	0.9671	0.3755	0.000234	1871|2|0	508270|237|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs190787427	19:3985426:G:C	C	0.361534	0.0260517	5.0172	1.342	0.4484	0.000117	1938|0|0	517565|122|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR UKB_Freeze_450_SAS Meta
rs377104055	19:3985429:T:C	C	0.361136	0.0234969	5.55049	1.3941	0.4650	0.000087	1850|0|0	416400|73|0	UKB_Freeze_450_AFR UKB_Freeze_450_EUR UPENN-PMBB_Freeze_One_AFR Meta
rs200921166	19:3985402:C:T	T	0.360523	0.00840259	15.4686	1.9179	0.5948	0.000064	1703|0|0	399187|51|0	UKB_Freeze_450_EUR Meta
rs774095261	19:3985425:C:A	A	0.352361	0.00521284	23.8177	2.1498	0.6275	0.000020	1850|0|0	416437|17|0	UKB_Freeze_450_AFR UKB_Freeze_450_EUR UPENN-PMBB_Freeze_One_AFR Meta
rs529755390	19:3985441:T:C	C	0.361172	0.00447913	29.123	2.2398	0.6493	0.000049	1873|0|0	508368|50|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs777439048	19:3985423:A:C	C	0.377494	0.00480048	29.6849	2.227	0.6618	0.000062	1873|0|0	508457|63|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs1196793724	19:3985436:C:G	G	0.364183	0.00328972	40.3162	2.4015	0.6740	0.000044	1703|0|0	399202|35|0	UKB_Freeze_450_EUR Meta
rs529755390	19:3985441:T:A	A	0.364438	0.0027381	48.5061	2.4955	0.6859	0.000047	1703|0|0	399119|38|0	UKB_Freeze_450_EUR Meta
NA	3985441:T:TGGCGGCGACCGGCGAC	CGGCGAC	0.364656	0.00182461	72.878	2.7029	0.7090	0.000044	1873|0|0	508368|45|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs190787427	19:3985426:G:A	A	0.365569	0.00170724	78.2788	2.7381	0.7132	0.000042	1703|0|0	399120|34|0	UKB_Freeze_450_EUR Meta
rs1280637004	19:3985463:G:A	A	0.364255	0.000412394	321.736	3.4611	0.7704	0.000024	1703|0|0	399215|19|0	UKB_Freeze_450_EUR Meta
rs563082396	19:3985436:C:A	A	0.364183	0.000353722	374.953	3.5393	0.7753	0.000034	1873|0|0	508468|35|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
NA	19:3985425:C:G	G	0.36411	0.000282174	469.838	3.6545	0.7822	0.000021	1703|0|0	399217|17|0	UKB_Freeze_450_EUR Meta
rs374912847	19:3985392:G:A	A	0.362584	0.000204629	642.464	3.8163	0.7904	0.000014	1703|0|0	399229|11|0	UKB_Freeze_450_EUR Meta
NA	19:3985455:G:A	A	0.363455	0.000175147	754.22	3.8969	0.7951	0.000016	1703|0|0	399227|13|0	UKB_Freeze_450_EUR Meta
rs750678552	19:3985430:C:G	G	0.35912	0.000113610	1135.11	4.1116	0.8033	0.000432	65|0|0	9192|8|0	UKB_Freeze_450_SAS Meta
rs776567094	19:3985428:G:A	A	0.365423	6.02E-05	2218.87	4.4447	0.8208	0.000019	1703|0|0	399218|15|0	UKB_Freeze_450_EUR Meta
rs369523513	19:3985436:G:C	C	0.366851	5.09E-05	2645.82	4.5325	0.8249	0.000018	1873|0|0	508462|18|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
NA	19:3985417:G:C	C	0.363855	2.93E-05	4517.18	4.8096	0.8335	0.000014	1703|0|0	399224|11|0	UKB_Freeze_450_EUR Meta
rs1027642860	19:3985460:A:C	C	0.36092	1.49E-05	8736.83	5.1503	0.8431	0.000009	1703|0|0	399229|7|0	UKB_Freeze_450_EUR Meta
rs779559837	19:3985444:C:A	A	0.391097	3.10E-05	4928.25	4.8172	0.8455	0.000110	170|0|0	109251|24|0	GHS_Freeze_145_MegaFreeze_EUR Meta
NA	19:3985444:C:T	T	0.382166	1.81E-05	8071.45	5.0807	0.8498	0.000022	1873|0|0	508485|22|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs776029456	19:3985405:C:G	G	0.374486	1.16E-05	12130.2	5.2989	0.8530	0.000017	1873|0|0	508513|5|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
NA	19:3985411:A:G	G	0.364948	5.36E-06	24871	5.6784	0.8591	0.000006	1703|0|0	399231|5|0	UKB_Freeze_450_EUR Meta
rs995814367	19:3985204:G:A	A	0.365204	3.21E-06	41519	5.9395	0.8653	0.000012	1703|0|0	399229|10|0	UKB_Freeze_450_EUR Meta
rs764194249	19:3985408:G:A	A	0.365204	2.04E-06	65358.2	6.171	0.8703	0.000006	1703|0|0	399234|5|0	UKB_Freeze_450_EUR Meta
NA	19:3985442:G:A	A	0.366228	1.12E-06	119957	6.4794	0.8768	0.000009	1703|0|0	399223|7|0	UKB_Freeze_450_EUR Meta
rs777439048	19:3985423:A:G	G	0.366667	6.02E-07	223245	6.7957	0.8826	0.000015	1703|0|0	399223|12|0	UKB_Freeze_450_EUR Meta
rs886610889	19:3985452:A:ACGG	ACGG	0.383391	9.78E-07	150305	6.5711	0.8840	0.000046	170|0|0	109273|10|0	GHS_Freeze_145_MegaFreeze_EUR Meta
rs748898673	19:3985399:A:G	G	0.366228	4.01E-07	334091	7.002	0.8859	0.000009	1703|0|0	399233|7|0	UKB_Freeze_450_EUR Meta
rs560636284	19:3985439:G:A	A	0.92441	0.310456	2.75251	0.5567	0.8877	0.000897	1870|3|0	507593|913|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs776567094	19:3985428:G:C	C	0.365825	2.96E-07	451572	7.1563	0.8882	0.000009	1703|0|0	399218|7|0	UKB_Freeze_450_EUR Meta
rs1019385884	19:3985467:G:A	A	0.366008	2.35E-07	569136	7.2741	0.8901	0.000007	1703|0|0	399229|6|0	UKB_Freeze_450_EUR Meta
rs1037024876	19:3985438:G:A	A	0.34294	5.19E-08	2.26E+06	8.0119	0.8937	0.000023	170|0|0	109273|5|0	GHS_Freeze_145_MegaFreeze_EUR Meta
rs754780163	19:3985431:G:A	A	0.366888	1.38E-07	973791	7.5469	0.8943	0.000012	1703|0|0	399227|10|0	UKB_Freeze_450_EUR Meta
NA	19:3985432:C:G	G	0.367034	7.63E-10	1.77E+08	10.2002	0.9217	0.000006	1703|0|0	399235|5|0	UKB_Freeze_450_EUR Meta
NA	19:3985449:A:G	G	0.375987	7.77E-10	1.82E+08	10.2028	0.9236	0.000027	170|0|0	109282|6|0	GHS_Freeze_145_MegaFreeze_EUR Meta
NA	19:3985446:G:A	A	0.367402	2.56E-13	5.28E+11	14.2826	0.9441	0.000006	1703|0|0	399232|5|0	UKB_Freeze_450_EUR Meta
rs373344045	19:3985424:G:A	A	1.06354	0.140046	8.07673	1.0344	0.9525	0.000243	1872|1|0	508283|247|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta

Supplementary Table 6. Evidence for association between the COVID-19 hospitalization phenotype and rs532051930 across different association tests.

Approach	Association test in individual studies	Approach used to combine results across studies	Association in UKB Europeans			Association in GHS Europeans			Association in UKB+GHS Europeans		
			OR (95% CI)	SE*	P-value	OR (95% CI)	SE*	P-value	OR (95% CI)	SE*	P-value
1 (default)	REGENIE Firth exact test, with covariates and LOCO	Inverse-variance fixed-effects meta-analysis	80.9 (13.1 - 499.5)	0.93	2.20E-06	134.8 (7.9 - 2301.3)	1.45	7.07E-04	93.9 (20.3 - 434.5)	0.78	6.17E-09
2		Sample size weighted meta-analysis							NA		3.14E-08
3		Meta-analysis of log-likelihood curves							85.6 (17.2 - 425.8)	0.82	5.51E-08
4	Firth exact test, no covariates	Inverse-variance fixed-effects meta-analysis	65.7 (16.9 - 195.3)	0.90	3.49E-06	92.1 (9.9 - 395.0)	1.4	0.00127	72.5 (16.4 - 321.0)	0.76	1.64E-08
5	Fisher's exact test (no covariates)		58.7 (10.6 - 218.5)	0.98	3.35E-05	64.6 (1.48 - 456.8)	1.75	0.017	60.1 (11.2 - 321.6)	0.86	1.70E-06
6	Logistic regression, with covariates		71.6 (15.6 - 241.7)	0.99	1.55E-05	106.5 (5.61 - 648.2)	1.74	0.00733	78.9 (14.6 - 425.0)	0.86	3.73E-07
7	Logistic regression, no covariates		58.7 (13.4 - 185.0)	0.96	2.37E-05	64.7 (3.51 - 340.4)	1.67	0.0123	60.2 (11.7 - 308.4)	0.83	9.00E-07
8	BinomiRare test, with covariates	Meta-analysis	NA		1.19E-05	NA		5.53E-05	NA		2.96E-07
9	Firth exact test, with covariates	Mega-analysis (UKB+GHS combined)	NA			NA			85.8 (17.2 - 427.2)	0.82	5.48E-08
10	Firth exact test, no covariates								54.4 (11.8 - 250.5)	0.78	2.91E-07
11	Fisher's exact test (no covariates)								49.4 (9.7 - 251.0)	0.83	2.53E-06
12	Logistic regression, with covariates								78.7 (14.6- 424.9)	0.86	3.88E-07
13	Logistic regression, no covariates								49.5 (9.9 - 246.2)	0.82	1.89E-06

*Re-calculated from the OR and p-value

Supplementary Table 7. No carriers of the rare variant rs532051930 in the promoter of EEF2 were observed in an additional 4,341 individuals with COVID-19.

Study	Reference	Total	Hospitalized	Severe	N COVID-19 cases	Heterozygote for rs532051930:A
					Of European|African|Asian|Hispanic|other ancestry	
GenOMICC	PMID 33307546	2969	2969	2969	2110 | 145 | 375 | NA | 339	0
Columbia University COVID-19 Biobank	https://www.medrxiv.org/content/10.1101/2020.12.18.20248226v2	1152	1082	479	67 | 463 | 33 | 506 | 83	0
Biobanque Québec Covid-19	https://www.medrxiv.org/content/10.1101/2020.12.18.20248226v2	220	128	62	154 | 30 | 29 | 7 | 0	0

Supplementary Table 8. Results from burden association tests for 167 genes located in eight loci described by Horowitz et al. (2021).

Trait	Gene	Burden test	MAF	Odds Ratio [95% CI]	P-value	N cases with RR|RA|AA genotype*	N controls with RR|RA|AA genotype*	AAF	GWAS SNP	Distance to GWAS SNP, bp	Distance to GWAS SNP, rank
COVID19 positive hospitalized vs COVID19 negative or unknown	CHAF1A	M1	<1%	25.216[4.947;128.539]	1.00E-04	1935|3|0	517687|45|0	0.00005	19:4719431:G:A	316669	16
COVID19 positive hospitalized vs COVID19 negative or unknown	CHAF1A	M3	<1%	25.216[4.947;128.539]	1.00E-04	1935|3|0	517687|45|0	0.00005	19:4719431:G:A	316669	16
COVID19 positive hospitalized vs COVID19 negative or unknown	SLC22A31	M1	<1%	5.583[1.807;17.256]	2.80E-03	1844|6|0	416071|402|0	0.00049	16:89117727	78271	3
COVID19 positive hospitalized vs COVID19 negative or unknown	SLC22A31	M3	<1%	5.583[1.807;17.256]	2.8E-03	1844|6|0	416071|402|0	0.00049	16:89117727	78271	3
COVID19 positive hospitalized vs COVID19 negative or unknown	SARDH	M1	<1%	2.367[1.315;4.259]	4.00E-03	2072|12|1	533477|1487|1	0.0014	9:133270015:A:C	393873	25
COVID19 positive hospitalized vs COVID19 negative or unknown	SHD	M1	<1%	5.283[1.619;17.242]	5.80E-03	1869|4|0	508290|242|0	0.00024	19:4719431:G:A	439368	22
COVID19 positive hospitalized vs COVID19 negative or unknown	CTB-50L17.10	M1	<1%	5.726[1.598;20.518]	7.40E-03	2017|3|0	525625|140|0	0.00014	19:4719431:G:A	247081	13
COVID19 positive hospitalized vs COVID19 negative or unknown	CTB-50L17.10	M3	<1%	5.726[1.598;20.518]	7.40E-03	2017|3|0	525625|140|0	0.00014	19:4719431:G:A	247081	13
COVID19 positive hospitalized vs COVID19 negative or unknown	DBH	M1	<1%	0.320[0.128;0.796]	1.40E-02	2083|2|0	532761|2204|0	0.00205	9:133270015:A:C	366356	22
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC14	M1	<1%	6.544[1.434;29.868]	1.50E-02	1936|2|0	517625|95|12	0.00012	19:51739497	96143	6
COVID19 positive hospitalized vs COVID19 negative or unknown	OLIG2	M1	<1%	12.046[1.255;115.574]	3.10E-02	1872|1|0	508456|76|0	0.00008	21:33252612:A:G	225750	7
COVID19 positive hospitalized vs COVID19 negative or unknown	OLIG2	M3	<1%	12.046[1.255;115.574]	3.10E-02	1872|1|0	508456|76|0	0.00008	21:33252612:A:G	225750	7
COVID19 positive hospitalized vs COVID19 negative or unknown	PSORS1C2	M1	<1%	5.176[1.151;23.275]	3.20E-02	1871|2|0	508350|182|0	0.00018	6:31153649:G:A	15699	4
COVID19 positive hospitalized vs COVID19 negative or unknown	PPP2R1A	M3	<1%	5.429[1.129;26.105]	3.50E-02	1871|2|0	508337|195|0	0.00019	19:51739497	450599	33
COVID19 positive hospitalized vs COVID19 negative or unknown	SH3GL1	M3	<1%	10.804[1.173;99.499]	3.80E-02	1872|1|0	508459|73|0	0.00007	19:4719431:G:A	357832	17
COVID19 positive hospitalized vs COVID19 negative or unknown	MICB	M1	<1%	2.106[1.007;4.401]	4.80E-02	2077|8|0	533921|1043|1	0.00098	6:31153649:G:A	344544	18
COVID19 positive hospitalized vs COVID19 negative or unknown	MICB	M3	<1%	2.106[1.007;4.401]	4.80E-02	2077|8|0	533921|1043|1	0.00098	6:31153649:G:A	344544	18
COVID19 positive hospitalized vs COVID19 negative or unknown	ATP6V1G2	M1	<1%	8.596[0.965;76.602]	5.40E-02	1872|1|0	508475|57|0	0.00006	6:31153649:G:A	391758	21
COVID19 positive hospitalized vs COVID19 negative or unknown	ATP6V1G2	M3	<1%	8.596[0.965;76.602]	5.40E-02	1872|1|0	508475|57|0	0.00006	6:31153649:G:A	391758	21
COVID19 positive hospitalized vs COVID19 negative or unknown	SURF6	M1	<1%	5.025[0.971;25.993]	5.40E-02	2016|2|0	525975|252|0	0.00024	9:133270015:A:C	61853	2
COVID19 positive hospitalized vs COVID19 negative or unknown	MYDGF	M3	<1%	0.343[0.115;1.024]	5.50E-02	2085|0|0	534469|496|0	0.00046	19:4719431:G:A	61427	2
COVID19 positive hospitalized vs COVID19 negative or unknown	XCR1	M1	<1%	3.068[0.967;9.733]	5.70E-02	2017|3|0	525432|333|0	0.00032	3:45859597:C:T	161348	6
COVID19 positive hospitalized vs COVID19 negative or unknown	C6orf15	M3	<1%	3.003[0.965;9.351]	5.80E-02	2016|4|0	525465|299|1	0.0003	6:31153649:G:A	42269	7
COVID19 positive hospitalized vs COVID19 negative or unknown	LARS2	M3	<1%	1.355[0.987;1.861]	6.00E-02	2036|48|1	524945|9982|38	0.00941	3:45859597:C:T	465144	11
COVID19 positive hospitalized vs COVID19 negative or unknown	PRRC2A	M3	<1%	0.716[0.505;1.016]	6.10E-02	2063|22|0	524933|10025|7	0.00937	6:31153649:G:A	469140	34
COVID19 positive hospitalized vs COVID19 negative or unknown	LIMD1	M3	<1%	2.202[0.962;5.038]	6.20E-02	2079|6|0	534053|912|0	0.00085	3:45859597:C:T	264718	8
COVID19 positive hospitalized vs COVID19 negative or unknown	FPR1	M1	<1%	9.521[0.887;102.209]	6.30E-02	2019|1|0	525731|34|0	0.00003	19:51739497	6444	1
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC14	M3	<1%	3.535[0.936;13.349]	6.30E-02	2003|2|0	526273|179|18	0.00021	19:51739497	96143	6
COVID19 positive hospitalized vs COVID19 negative or unknown	CYBA	M3	<1%	2.843[0.930;8.693]	6.70E-02	2080|5|0	534405|560|0	0.00053	16:89117727	474375	20
COVID19 positive hospitalized vs COVID19 negative or unknown	OLIG1	M1	<1%	7.354[0.856;63.204]	6.90E-02	1872|1|0	508454|78|0	0.00008	21:33252612:A:G	182366	5
COVID19 positive hospitalized vs COVID19 negative or unknown	OLIG1	M3	<1%	7.354[0.856;63.204]	6.90E-02	1872|1|0	508454|78|0	0.00008	21:33252612:A:G	182366	5
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF615	M1	<1%	0.368[0.121;1.117]	7.80E-02	2085|0|0	534154|810|1	0.00076	19:51739497	253382	17
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF615	M3	<1%	0.368[0.121;1.117]	7.80E-02	2085|0|0	534154|810|1	0.00076	19:51739497	253382	17
COVID19 positive hospitalized vs COVID19 negative or unknown	KDM4B	M3	<1%	2.146[0.916;5.028]	7.90E-02	2077|8|0	533186|1778|1	0.00166	19:4719431:G:A	313459	15
COVID19 positive hospitalized vs COVID19 negative or unknown	CPNE7	M1	<1%	2.509[0.871;7.222]	8.80E-02	2079|6|0	534223|742|0	0.0007	16:89117727	458170	18
COVID19 positive hospitalized vs COVID19 negative or unknown	DBH	M3	<1%	0.824[0.657;1.033]	9.30E-02	2021|64|0	514043|20887|35	0.01957	9:133270015:A:C	366356	22
COVID19 positive hospitalized vs COVID19 negative or unknown	SURF1	M1	<1%	1.734[0.905;3.321]	9.70E-02	2075|10|0	533511|1454|0	0.00136	9:133270015:A:C	81897	6
COVID19 positive hospitalized vs COVID19 negative or unknown	CTU2	M1	<1%	2.046[0.868;4.822]	1.00E-01	2076|9|0	533716|1247|2	0.00117	16:89117727	411197	14
COVID19 positive hospitalized vs COVID19 negative or unknown	FEM1A	M1	<1%	3.778[0.670;21.285]	1.30E-01	2015|3|0	525914|313|0	0.0003	19:4719431:G:A	72423	4
COVID19 positive hospitalized vs COVID19 negative or unknown	FEM1A	M3	<1%	3.778[0.670;21.285]	1.30E-01	2015|3|0	525914|313|0	0.0003	19:4719431:G:A	72423	4
COVID19 positive hospitalized vs COVID19 negative or unknown	LZTFL1	M3	<1%	2.578[0.756;8.800]	1.30E-01	2082|3|0	534504|460|1	0.00043	3:45859597:C:T	33284	1
COVID19 positive hospitalized vs COVID19 negative or unknown	SURF2	M1	<1%	0.471[0.176;1.262]	1.30E-01	2084|1|0	534038|927|0	0.00086	9:133270015:A:C	86577	7
COVID19 positive hospitalized vs COVID19 negative or unknown	ARRDC5	M3	<1%	2.513[0.744;8.487]	1.40E-01	2080|5|0	534263|702|0	0.00066	19:4719431:G:A	171614	7
COVID19 positive hospitalized vs COVID19 negative or unknown	FLOT1	M3	<1%	1.969[0.802;4.836]	1.40E-01	2077|8|0	533722|1242|1	0.00117	6:31153649:G:A	425534	26
COVID19 positive hospitalized vs COVID19 negative or unknown	IGLON5	M1	<1%	19.079[0.389;936.241]	1.40E-01	1872|1|0	508445|87|0	0.00009	19:51739497	427650	32
COVID19 positive hospitalized vs COVID19 negative or unknown	SLC6A20	M1	<1%	0.462[0.161;1.328]	1.50E-01	2085|0|0	534061|904|0	0.00084	3:45859597:C:T	101161	5
COVID19 positive hospitalized vs COVID19 negative or unknown	MAT2B	M3	<1%	0.473[0.168;1.330]	1.60E-01	2084|1|0	534078|887|0	0.00083	5:163300447	202947	4
COVID19 positive hospitalized vs COVID19 negative or unknown	SARDH	M3	<1%	1.293[0.905;1.848]	1.60E-01	2050|34|1	528071|6891|3	0.00645	9:133270015:A:C	393873	25
COVID19 positive hospitalized vs COVID19 negative or unknown	TSC1	M3	<1%	0.741[0.490;1.121]	1.60E-01	2069|16|0	528190|6768|7	0.00633	9:133270015:A:C	373781	23
COVID19 positive hospitalized vs COVID19 negative or unknown	MUC21	M1	<1%	0.367[0.086;1.555]	1.70E-01	2020|0|0	525263|501|1	0.00048	6:31153649:G:A	169691	10
COVID19 positive hospitalized vs COVID19 negative or unknown	MUC21	M3	<1%	0.367[0.086;1.555]	1.70E-01	2020|0|0	525263|501|1	0.00048	6:31153649:G:A	169691	10
COVID19 positive hospitalized vs COVID19 negative or unknown	PLIN5	M1	<1%	0.486[0.172;1.374]	1.70E-01	2084|1|0	534032|931|2	0.00087	19:4719431:G:A	195904	11
COVID19 positive hospitalized vs COVID19 negative or unknown	PLIN5	M3	<1%	0.486[0.172;1.374]	1.70E-01	2084|1|0	534032|931|2	0.00087	19:4719431:G:A	195904	11
COVID19 positive hospitalized vs COVID19 negative or unknown	LIMD1	M1	<1%	11.539[0.303;439.203]	1.90E-01	1872|1|0	508431|101|0	0.0001	3:45859597:C:T	264718	8
COVID19 positive hospitalized vs COVID19 negative or unknown	MVD	M1	<1%	0.362[0.078;1.673]	1.90E-01	1938|0|0	517333|399|0	0.00038	16:89117727	465203	19
COVID19 positive hospitalized vs COVID19 negative or unknown	NCR3	M1	<1%	0.373[0.086;1.608]	1.90E-01	2020|0|0	525351|414|0	0.00039	6:31153649:G:A	435417	30
COVID19 positive hospitalized vs COVID19 negative or unknown	RNF166	M3	<1%	2.052[0.696;6.046]	1.90E-01	2016|4|0	525167|598|0	0.00057	16:89117727	420160	15
COVID19 positive hospitalized vs COVID19 negative or unknown	SACM1L	M1	<1%	3.293[0.554;19.585]	1.90E-01	1937|1|0	517584|148|0	0.00014	3:45859597:C:T	170132	7
COVID19 positive hospitalized vs COVID19 negative or unknown	CCDC94	M1	<1%	3.763[0.497;28.456]	2.00E-01	2019|1|0	525606|159|0	0.00015	19:4719431:G:A	472285	23
COVID19 positive hospitalized vs COVID19 negative or unknown	SACM1L	M3	<1%	1.982[0.690;5.692]	2.00E-01	2080|5|0	534178|786|1	0.00074	3:45859597:C:T	170132	7
COVID19 positive hospitalized vs COVID19 negative or unknown	TRAPPC2L	M1	<1%	0.759[0.498;1.158]	2.00E-01	2069|16|0	528171|6783|11	0.00635	16:89117727	260577	8
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF616	M1	<1%	0.493[0.166;1.465]	2.00E-01	2004|1|0	525530|940|0	0.00089	19:51739497	375320	28
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF616	M3	<1%	0.493[0.166;1.465]	2.00E-01	2004|1|0	525530|940|0	0.00089	19:51739497	375320	28
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF836	M1	<1%	0.363[0.076;1.725]	2.00E-01	2085|0|0	534615|350|0	0.00033	19:51739497	415374	31
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF836	M3	<1%	0.363[0.076;1.725]	2.00E-01	2085|0|0	534615|350|0	0.00033	19:51739497	415374	31
COVID19 positive hospitalized vs COVID19 negative or unknown	CEACAM18	M1	<1%	0.365[0.075;1.773]	2.10E-01	2005|0|0	526042|428|0	0.0004	19:51739497	260855	18
COVID19 positive hospitalized vs COVID19 negative or unknown	CEACAM18	M3	<1%	0.365[0.075;1.773]	2.10E-01	2005|0|0	526042|428|0	0.0004	19:51739497	260855	18
COVID19 positive hospitalized vs COVID19 negative or unknown	DNAJC28	M3	<1%	0.561[0.228;1.381]	2.10E-01	2083|2|0	533837|1128|0	0.00105	21:33252612:A:G	235614	8
COVID19 positive hospitalized vs COVID19 negative or unknown	APRT	M3	<1%	0.502[0.168;1.501]	2.20E-01	2084|1|0	534131|834|0	0.00078	16:89117727	308030	10
COVID19 positive hospitalized vs COVID19 negative or unknown	BAG6	M3	<1%	0.713[0.416;1.224]	2.20E-01	2076|9|0	531625|3337|3	0.00312	6:31153649:G:A	485481	36
COVID19 positive hospitalized vs COVID19 negative or unknown	HMMR	M3	<1%	0.688[0.377;1.254]	2.20E-01	2078|7|0	532229|2730|6	0.00256	5:163300447	160245	3
COVID19 positive hospitalized vs COVID19 negative or unknown	SLC6A20	M3	<1%	0.721[0.428;1.216]	2.20E-01	2076|9|0	531236|3727|2	0.00348	3:45859597:C:T	101161	5
COVID19 positive hospitalized vs COVID19 negative or unknown	SPACA9	M1	<1%	0.368[0.075;1.806]	2.20E-01	2085|0|0	534523|440|2	0.00041	9:133270015:A:C	386068	24
COVID19 positive hospitalized vs COVID19 negative or unknown	VARS2	M1	<1%	0.768[0.503;1.174]	2.20E-01	2069|16|0	529226|5729|10	0.00537	6:31153649:G:A	239238	14
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF841	M1	<1%	0.562[0.225;1.399]	2.20E-01	2083|2|0	533694|1271|0	0.00119	19:51739497	325609	22
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF841	M3	<1%	0.562[0.225;1.399]	2.20E-01	2083|2|0	533694|1271|0	0.00119	19:51739497	325609	22
COVID19 positive hospitalized vs COVID19 negative or unknown	DDR1	M1	<1%	0.365[0.071;1.871]	2.30E-01	1938|0|0	517314|418|0	0.0004	6:31153649:G:A	268430	17
COVID19 positive hospitalized vs COVID19 negative or unknown	FYCO1	M3	<1%	1.270[0.862;1.871]	2.30E-01	2055|30|0	527455|7494|16	0.00703	3:45859597:C:T	62167	3
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNGR2	M3	<1%	8.396[0.261;270.048]	2.30E-01	1872|1|0	508441|91|0	0.00009	21:33252612:A:G	150931	4
COVID19 positive hospitalized vs COVID19 negative or unknown	TCF19	M3	<1%	0.506[0.167;1.534]	2.30E-01	2084|1|0	534099|865|1	0.00081	6:31153649:G:A	5820	1
COVID19 positive hospitalized vs COVID19 negative or unknown	VARS2	M3	<1%	0.820[0.593;1.135]	2.30E-01	2055|30|0	525693|9261|10	0.00867	6:31153649:G:A	239238	14
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR2	M1	<1%	2.077[0.620;6.961]	2.40E-01	2082|3|0	534277|688|0	0.00064	21:33252612:A:G	10690	1

COVID19 positive hospitalized vs COVID19 negative or unknown	SURF6	M3	<1%	1.442[0.785;2.651]	2.40E-01	2071|14|0	532573|2388|4	0.00224	9:133270015:A:C	61853	2
COVID19 positive hospitalized vs COVID19 negative or unknown	AC074141.1	M1	<1%	0.515[0.167;1.587]	2.50E-01	2084|1|0	534249|715|1	0.00067	19:51739497	133034	9
COVID19 positive hospitalized vs COVID19 negative or unknown	AC074141.1	M3	<1%	0.515[0.167;1.587]	2.50E-01	2084|1|0	534249|715|1	0.00067	19:51739497	133034	9
COVID19 positive hospitalized vs COVID19 negative or unknown	MED22	M1	<1%	2.725[0.493;15.068]	2.50E-01	1872|1|0	508339|193|0	0.00019	9:133270015:A:C	71489	4
COVID19 positive hospitalized vs COVID19 negative or unknown	CCNG1	M1	<1%	2.100[0.575;7.670]	2.60E-01	2081|4|0	534370|595|0	0.00056	5:163300447	138809	1
COVID19 positive hospitalized vs COVID19 negative or unknown	MYDGF	M1	<1%	0.315[0.042;2.346]	2.60E-01	2085|0|0	534773|192|0	0.00018	19:4719431:G:A	61427	2
COVID19 positive hospitalized vs COVID19 negative or unknown	NCR3	M1	<1%	0.363[0.063;2.083]	2.60E-01	1873|0|0	508231|301|0	0.00029	6:31153649:G:A	435417	30
COVID19 positive hospitalized vs COVID19 negative or unknown	SON	M3	<1%	1.154[0.897;1.483]	2.60E-01	2014|70|1	518373|16570|22	0.01553	21:33252612:A:G	290480	10
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR2	M3	<1%	1.968[0.598;6.469]	2.70E-01	2082|3|0	534253|712|0	0.00067	21:33252612:A:G	10690	1
COVID19 positive hospitalized vs COVID19 negative or unknown	SPG7	M1	<1%	1.418[0.762;2.638]	2.70E-01	2075|10|0	532986|1978|1	0.00185	16:89117727	390690	12
COVID19 positive hospitalized vs COVID19 negative or unknown	GALNS	M1	<1%	0.370[0.061;2.257]	2.80E-01	1953|0|0	516724|303|0	0.00029	16:89117727	303289	9
COVID19 positive hospitalized vs COVID19 negative or unknown	POU5F1	M3	<1%	0.363[0.057;2.295]	2.80E-01	1873|0|0	508235|297|0	0.00029	6:31153649:G:A	10951	2
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC8	M1	<1%	2.359[0.503;11.052]	2.80E-01	2017|3|0	525367|398|0	0.00038	19:51739497	287119	20
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF432	M1	<1%	1.745[0.629;4.839]	2.80E-01	2078|7|0	533544|1421|0	0.00133	19:51739497	294222	21
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF432	M3	<1%	1.745[0.629;4.839]	2.80E-01	2078|7|0	533544|1421|0	0.00133	19:51739497	294222	21
COVID19 positive hospitalized vs COVID19 negative or unknown	DONSON	M3	<1%	1.265[0.809;1.979]	3.00E-01	2061|24|0	530103|4855|7	0.00456	21:33252612:A:G	325694	11
COVID19 positive hospitalized vs COVID19 negative or unknown	SURF2	M1	<1%	0.532[0.161;1.757]	3.00E-01	2084|1|0	534311|654|0	0.00061	9:133270015:A:C	86577	7
COVID19 positive hospitalized vs COVID19 negative or unknown	SURF4	M1	<1%	5.574[0.219;142.075]	3.00E-01	1937|1|0	517635|96|1	0.0001	9:133270015:A:C	93448	8
COVID19 positive hospitalized vs COVID19 negative or unknown	IGLON5	M3	<1%	1.781[0.591;5.367]	3.10E-01	2080|5|0	534127|838|0	0.00078	19:51739497	427650	32
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC8	M3	<1%	2.209[0.485;10.070]	3.10E-01	2082|3|0	534553|412|0	0.00039	19:51739497	287119	20
COVID19 positive hospitalized vs COVID19 negative or unknown	ADAMTSL2	M1	<1%	0.674[0.308;1.477]	3.20E-01	2081|4|0	533538|1420|7	0.00134	9:133270015:A:C	264725	19
COVID19 positive hospitalized vs COVID19 negative or unknown	ARRDC5	M1	<1%	4.900[0.209;114.787]	3.20E-01	1872|1|0	508406|126|0	0.00012	19:4719431:G:A	171614	7
COVID19 positive hospitalized vs COVID19 negative or unknown	GFI1B	M3	<1%	0.761[0.444;1.304]	3.20E-01	2075|10|0	531725|3238|2	0.00303	9:133270015:A:C	283337	20
COVID19 positive hospitalized vs COVID19 negative or unknown	LIM2	M3	<1%	1.580[0.643;3.881]	3.20E-01	2078|7|0	533775|1190|0	0.00111	19:51739497	359297	25
COVID19 positive hospitalized vs COVID19 negative or unknown	OBP2B	M1	<1%	1.214[0.828;1.778]	3.20E-01	2053|32|0	528194|6771|0	0.00633	9:133270015:A:C	64687	3
COVID19 positive hospitalized vs COVID19 negative or unknown	OBP2B	M3	<1%	1.214[0.828;1.778]	3.20E-01	2053|32|0	528194|6771|0	0.00633	9:133270015:A:C	64687	3
COVID19 positive hospitalized vs COVID19 negative or unknown	PRRC2A	M1	<1%	0.638[0.262;1.553]	3.20E-01	1870|3|0	505561|2971|0	0.00291	6:31153649:G:A	469140	34
COVID19 positive hospitalized vs COVID19 negative or unknown	CDT1	M1	<1%	2.121[0.474;9.487]	3.30E-01	2015|3|0	525792|435|0	0.00041	16:89117727	313896	11
COVID19 positive hospitalized vs COVID19 negative or unknown	RPL7A	M3	<1%	0.364[0.048;2.778]	3.30E-01	1953|0|0	516804|223|0	0.00021	9:133270015:A:C	78228	5
COVID19 positive hospitalized vs COVID19 negative or unknown	TCF19	M1	<1%	0.369[0.050;2.706]	3.30E-01	1938|0|0	517437|294|1	0.00028	6:31153649:G:A	5820	1
COVID19 positive hospitalized vs COVID19 negative or unknown	XCR1	M3	<1%	1.753[0.566;5.428]	3.30E-01	2081|4|0	534290|675|0	0.00063	3:45859597:C:T	161348	6
COVID19 positive hospitalized vs COVID19 negative or unknown	CDSN	M3	<1%	0.680[0.310;1.494]	3.40E-01	2074|11|0	531401|3563|1	0.00333	6:31153649:G:A	37625	6
COVID19 positive hospitalized vs COVID19 negative or unknown	CEL	M1	<1%	0.802[0.513;1.256]	3.40E-01	2070|15|0	530001|4944|20	0.00465	9:133270015:A:C	208022	16
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR9	M1	<1%	0.354[0.041;3.080]	3.50E-01	1938|0|0	517545|187|0	0.00018	3:45859597:C:T	35336	2
COVID19 positive hospitalized vs COVID19 negative or unknown	CTU2	M3	<1%	1.180[0.834;1.670]	3.50E-01	2047|38|0	526415|8544|6	0.008	16:89117727	411197	14
COVID19 positive hospitalized vs COVID19 negative or unknown	SPACA9	M3	<1%	0.689[0.317;1.498]	3.50E-01	2081|4|0	533295|1668|2	0.00156	9:133270015:A:C	386068	24
COVID19 positive hospitalized vs COVID19 negative or unknown	CEL	M3	<1%	0.832[0.564;1.229]	3.60E-01	2064|21|0	528589|6355|21	0.00598	9:133270015:A:C	208022	16
COVID19 positive hospitalized vs COVID19 negative or unknown	CRYZL1	M1	<1%	0.363[0.042;3.132]	3.60E-01	1938|0|0	517520|212|0	0.0002	21:33252612:A:G	337178	12
COVID19 positive hospitalized vs COVID19 negative or unknown	FAM163B	M3	<1%	1.436[0.647;3.191]	3.70E-01	2066|19|0	530396|4569|0	0.00427	9:133270015:A:C	309006	21
COVID19 positive hospitalized vs COVID19 negative or unknown	MPND	M1	<1%	0.376[0.044;3.228]	3.70E-01	2020|0|0	525540|224|1	0.00021	19:4719431:G:A	375838	18
COVID19 positive hospitalized vs COVID19 negative or unknown	C21orf62	M1	<1%	0.362[0.038;3.417]	3.80E-01	1938|0|0	517567|165|0	0.00016	21:33252612:A:G	458851	13
COVID19 positive hospitalized vs COVID19 negative or unknown	C21orf62	M3	<1%	0.362[0.038;3.417]	3.80E-01	1938|0|0	517567|165|0	0.00016	21:33252612:A:G	458851	13
COVID19 positive hospitalized vs COVID19 negative or unknown	PIEZO1	M1	<1%	0.722[0.350;1.488]	3.80E-01	2080|5|0	533243|1722|0	0.00161	16:89117727	402123	13
COVID19 positive hospitalized vs COVID19 negative or unknown	ACSF3	M1	<1%	0.874[0.642;1.189]	3.90E-01	2048|37|0	524213|10735|17	0.01006	16:89117727	17046	1
COVID19 positive hospitalized vs COVID19 negative or unknown	HMMR	M1	<1%	0.722[0.342;1.522]	3.90E-01	2080|5|0	533239|1721|5	0.00162	5:163300447	160245	3
COVID19 positive hospitalized vs COVID19 negative or unknown	SHD	M3	<1%	1.511[0.585;3.902]	3.90E-01	2079|6|0	533918|1045|2	0.00098	19:4719431:G:A	439368	22
COVID19 positive hospitalized vs COVID19 negative or unknown	TICAM1	M1	<1%	3.730[0.189;73.610]	3.90E-01	1872|1|0	508368|164|0	0.00016	19:4719431:G:A	96807	5
COVID19 positive hospitalized vs COVID19 negative or unknown	TICAM1	M3	<1%	3.657[0.188;71.218]	3.90E-01	1872|1|0	508365|167|0	0.00016	19:4719431:G:A	96807	5
COVID19 positive hospitalized vs COVID19 negative or unknown	SURF1	M3	<1%	1.308[0.702;2.439]	4.00E-01	2072|13|0	532627|2338|0	0.00219	9:133270015:A:C	81897	6
COVID19 positive hospitalized vs COVID19 negative or unknown	CXCR6	M1	<1%	0.364[0.034;3.941]	4.10E-01	1940|0|0	517072|198|0	0.00019	3:45859597:C:T	86884	4
COVID19 positive hospitalized vs COVID19 negative or unknown	DDX39B	M3	<1%	0.367[0.034;3.973]	4.10E-01	1873|0|0	508265|267|0	0.00026	6:31153649:G:A	376784	20
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17C	M1	<1%	1.666[0.496;5.595]	4.10E-01	2081|4|0	534261|704|0	0.00066	16:89117727	479086	21
COVID19 positive hospitalized vs COVID19 negative or unknown	UBXN6	M1	<1%	0.368[0.034;3.984]	4.10E-01	2020|0|0	525583|182|0	0.00017	19:4719431:G:A	273934	14
COVID19 positive hospitalized vs COVID19 negative or unknown	PPP1R18	M1	<1%	0.365[0.031;4.278]	4.10E-01	1873|0|0	508356|176|0	0.00017	6:31153649:G:A	476381	35
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF614	M1	<1%	2.130[0.339;13.393]	4.20E-01	2083|2|0	534709|256|0	0.00024	19:51739497	273639	19
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF614	M3	<1%	2.130[0.339;13.393]	4.20E-01	2083|2|0	534709|256|0	0.00024	19:51739497	273639	19
COVID19 positive hospitalized vs COVID19 negative or unknown	ETFB	M3	<1%	1.329[0.655;2.696]	4.30E-01	2077|8|0	533213|1751|1	0.00164	19:51739497	394287	29
COVID19 positive hospitalized vs COVID19 negative or unknown	ACSF3	M1	<1%	0.683[0.258;1.808]	4.40E-01	2082|3|0	534093|872|0	0.00081	16:89117727	17046	1
COVID19 positive hospitalized vs COVID19 negative or unknown	ANKRD11	M3	<1%	1.168[0.788;1.733]	4.40E-01	2056|29|0	528339|6623|3	0.0062	16:89117727	150750	5
COVID19 positive hospitalized vs COVID19 negative or unknown	DNAJC28	M3	<1%	0.762[0.384;1.512]	4.40E-01	2079|6|0	533031|1934|0	0.00181	21:33252612:A:G	235614	8
COVID19 positive hospitalized vs COVID19 negative or unknown	FYCO1	M1	<1%	1.425[0.575;3.534]	4.40E-01	2080|5|0	533865|1098|2	0.00103	3:45859597:C:T	62167	3
COVID19 positive hospitalized vs COVID19 negative or unknown	GALNS	M3	<1%	0.747[0.357;1.563]	4.40E-01	2080|5|0	533141|1823|1	0.0017	16:89117727	303289	9
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNGR2	M3	<1%	3.072[0.176;53.618]	4.40E-01	1872|1|0	508406|124|0	0.00012	21:33252612:A:G	150931	4
COVID19 positive hospitalized vs COVID19 negative or unknown	PLIN3	M3	<1%	0.591[0.154;2.274]	4.40E-01	2084|1|0	534513|451|1	0.00042	19:4719431:G:A	119760	6
COVID19 positive hospitalized vs COVID19 negative or unknown	PLIN4	M3	<1%	1.203[0.756;1.912]	4.40E-01	2064|21|0	530811|4133|21	0.00391	19:4719431:G:A	214973	12
COVID19 positive hospitalized vs COVID19 negative or unknown	TRAPPC2L	M3	<1%	0.856[0.575;1.273]	4.40E-01	2064|21|0	527447|7504|14	0.00703	16:89117727	260577	8
COVID19 positive hospitalized vs COVID19 negative or unknown	ADAMTSL2	M3	<1%	0.727[0.317;1.669]	4.50E-01	2081|4|0	533744|1214|7	0.00115	9:133270015:A:C	264725	19
COVID19 positive hospitalized vs COVID19 negative or unknown	GART	M1	<1%	1.393[0.591;3.285]	4.50E-01	2078|7|0	533417|1548|0	0.00145	21:33252612:A:G	251511	9
COVID19 positive hospitalized vs COVID19 negative or unknown	IL10RB	M1	<1%	2.965[0.174;50.555]	4.50E-01	1937|1|0	517584|148|0	0.0014	21:33252612:A:G	13853	2
COVID19 positive hospitalized vs COVID19 negative or unknown	SLC2A6	M1	<1%	0.377[0.030;4.670]	4.50E-01	2085|0|0	534801|163|1	0.0015	9:133270015:A:C	202005	15
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF649	M1	<1%	0.367[0.027;4.993]	4.50E-01	1873|0|0	508363|169|0	0.00017	19:51739497	151120	11
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF649	M3	<1%	0.367[0.027;4.993]	4.50E-01	1873|0|0	508363|169|0	0.00017	19:51739497	151120	11
COVID19 positive hospitalized vs COVID19 negative or unknown	AIF1	M1	<1%	0.364[0.025;5.368]	4.60E-01	1938|0|0	517587|145|0	0.0014	6:31153649:G:A	461680	32
COVID19 positive hospitalized vs COVID19 negative or unknown	SEMA6B	M1	<1%	0.359[0.023;5.521]	4.60E-01	1873|0|0	508407|125|0	0.00012	19:4719431:G:A	176518	8
COVID19 positive hospitalized vs COVID19 negative or unknown	SEMA6B	M3	<1%	0.359[0.023;5.521]	4.60E-01	1873|0|0	508407|125|0	0.00012	19:4719431:G:A	176518	8
COVID19 positive hospitalized vs COVID19 negative or unknown	EBI3	M1	<1%	0.366[0.023;5.774]	4.70E-01	1873|0|0	508388|144|0	0.00014	19:4719431:G:A	489881	24
COVID19 positive hospitalized vs COVID19 negative or unknown	FLOT1	M1	<1%	0.365[0.023;5.722]	4.70E-01	1873|0|0	508397|135|0	0.00013	6:31153649:G:A	425534	26
COVID19 positive hospitalized vs COVID19 negative or unknown	MED22	M3	<1%	0.600[0.150;2.401]	4.70E-01	2084|1|0	534484|481|0	0.00045	9:133270015:A:C	71489	4
COVID19 positive hospitalized vs COVID19 negative or unknown	NKG7	M3	<1%	1.921[0.322;11.460]	4.70E-01	1871|2|0	508207|325|0	0.00032	16:89117727	367721	26
COVID19 positive hospitalized vs COVID19 negative or unknown	SLC2A6	M3	<1%	1.403[0.555;3.542]	4.70E-01	2079|6|0	533752|1212|1	0.00114	9:133270015:A:C	202005	15
COVID19 positive hospitalized vs COVID19 negative or unknown	C19orf84	M1	<1%	0.363[0.021;6.289]	4.90E-01	1770|0|0	407837|141|0	0.00017	19:51739497	350514	24
COVID19 positive hospitalized vs COVID19 negative or unknown	C19orf84	M3	<1%	0.363[0.021;6.289]	4.90E-01	1770|0|0	407837|141|0	0.00017	19:51739497	350514	24
COVID19 positive hospitalized vs COVID19 negative or unknown	LZTFL1	M3	<1%	0.368[0.022;6.171]	4.90E-01	1873|0|0	508386|146|0	0.00014	3:45859597:C:T	33284	1
COVID19 positive hospitalized vs COVID19 negative or unknown	TMIGD2	M1	<1%	1.872[0.319;11.005]	4.90E-01	2016|2|0	525931|295|1	0.00028	19:4719431:G:A	426833	21
COVID19 positive hospitalized vs COVID19 negative or unknown	TMIGD2	M3	<1%	1.872[0.319;11.005]	4.90E-01	2016|2|0	525931|295|1	0.00028	19:4719431:G:A	426833	21
COVID19 positive hospitalized vs COVID19 negative or unknown	GART	M3	<1%	1.178[0.728;1.903]	5.00E-01	2065|20|0	530814|4149|2	0.00389	21:33252612:A:G	251511	9

COVID19 positive hospitalized vs COVID19 negative or unknown	LTB	M3	<1%	0.359[0.018;7.128]	5.00E-01	1873|0|0	508445|87|0	0.00009	6:31153649:G:A	427059	27
COVID19 positive hospitalized vs COVID19 negative or unknown	NUDCD2	M3	<1%	0.607[0.142;2.598]	5.00E-01	2084|1|0	534582|383|0	0.00036	5:163300447	153519	2
COVID19 positive hospitalized vs COVID19 negative or unknown	SURF4	M3	<1%	0.612[0.149;2.513]	5.00E-01	2084|1|0	534492|472|1	0.00044	9:133270015:A:C	93448	8
COVID19 positive hospitalized vs COVID19 negative or unknown	C6orf15	M1	<1%	0.370[0.019;7.362]	5.10E-01	1873|0|0	508407|124|1	0.00012	6:31153649:G:A	42269	7
COVID19 positive hospitalized vs COVID19 negative or unknown	CDT1	M3	<1%	0.840[0.500;1.412]	5.10E-01	2073|12|0	532038|2920|7	0.00274	16:89117727	313896	11
COVID19 positive hospitalized vs COVID19 negative or unknown	FPR2	M1	<1%	0.365[0.019;7.103]	5.10E-01	1953|0|0	516947|80|0	0.00008	19:51739497	29161	3
COVID19 positive hospitalized vs COVID19 negative or unknown	FPR2	M3	<1%	0.365[0.019;7.103]	5.10E-01	1953|0|0	516947|80|0	0.00008	19:51739497	29161	3
COVID19 positive hospitalized vs COVID19 negative or unknown	MPND	M3	<1%	1.146[0.765;1.717]	5.10E-01	2059|25|1	528772|6178|15	0.0058	19:4719431:G:A	375838	18
COVID19 positive hospitalized vs COVID19 negative or unknown	GTF3C5	M3	<1%	1.236[0.644;2.372]	5.20E-01	2074|11|0	532496|2469|0	0.00231	9:133270015:A:C	239004	17
COVID19 positive hospitalized vs COVID19 negative or unknown	MVD	M3	<1%	0.778[0.361;1.676]	5.20E-01	2080|5|0	533277|1687|1	0.00158	16:89117727	465203	19
COVID19 positive hospitalized vs COVID19 negative or unknown	CBFA2T3	M3	<1%	2.336[0.164;33.240]	5.30E-01	1872|1|0	508348|183|1	0.00018	16:89117727	240752	6
COVID19 positive hospitalized vs COVID19 negative or unknown	CCNG1	M1	<1%	0.370[0.017;7.948]	5.30E-01	2020|0|0	525664|101|0	0.0001	5:163300447	138809	1
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17C	M3	<1%	0.364[0.016;8.237]	5.30E-01	1873|0|0	508415|117|0	0.00011	16:89117727	479086	21
COVID19 positive hospitalized vs COVID19 negative or unknown	AC018755.18	M3	<1%	1.134[0.757;1.697]	5.40E-01	2058|27|0	528870|6077|18	0.00572	19:51739497	127267	7
COVID19 positive hospitalized vs COVID19 negative or unknown	HAS1	M3	<1%	1.169[0.709;1.925]	5.40E-01	2067|18|0	530804|4159|2	0.00389	19:51739497	26071	2
COVID19 positive hospitalized vs COVID19 negative or unknown	PLIN3	M1	<1%	0.640[0.151;2.712]	5.40E-01	2084|1|0	534575|389|1	0.00036	19:4719431:G:A	119760	6
COVID19 positive hospitalized vs COVID19 negative or unknown	APRT	M3	<1%	0.637[0.147;2.755]	5.50E-01	1939|1|0	516800|470|0	0.00045	16:89117727	308030	10
COVID19 positive hospitalized vs COVID19 negative or unknown	FPR3	M3	<1%	0.379[0.016;9.247]	5.50E-01	1940|0|0	517201|69|0	0.00007	19:51739497	84251	5
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF577	M1	<1%	0.710[0.232;2.175]	5.50E-01	2083|2|0	534235|729|1	0.00068	19:51739497	133034	10
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF577	M3	<1%	0.710[0.232;2.175]	5.50E-01	2083|2|0	534235|729|1	0.00068	19:51739497	133034	10
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR3	M3	<1%	0.839[0.467;1.509]	5.60E-01	2076|9|0	532705|2252|8	0.00212	3:45859597:C:T	404806	10
COVID19 positive hospitalized vs COVID19 negative or unknown	REXO4	M1	<1%	1.410[0.440;4.521]	5.60E-01	2081|4|0	534520|442|3	0.00042	9:133270015:A:C	136937	11
COVID19 positive hospitalized vs COVID19 negative or unknown	ABO	M1	<1%	1.163[0.694;1.949]	5.70E-01	2068|17|0	531205|3752|8	0.00352	9:133270015:A:C	14414	1
COVID19 positive hospitalized vs COVID19 negative or unknown	ABO	M3	<1%	1.163[0.694;1.949]	5.70E-01	2068|17|0	531205|3752|8	0.00352	9:133270015:A:C	14414	1
COVID19 positive hospitalized vs COVID19 negative or unknown	CRYZL1	M3	<1%	0.755[0.288;1.982]	5.70E-01	2082|3|0	533923|1041|1	0.00097	21:33252612:A:G	337178	12
COVID19 positive hospitalized vs COVID19 negative or unknown	DPP9	M1	<1%	0.364[0.011;12.326]	5.70E-01	1938|0|0	517629|103|0	0.0001	19:4719431:G:A	42868	1
COVID19 positive hospitalized vs COVID19 negative or unknown	GTF2H4	M1	<1%	0.648[0.147;2.863]	5.70E-01	1872|1|0	508061|471|0	0.00046	6:31153649:G:A	244613	15
COVID19 positive hospitalized vs COVID19 negative or unknown	GTF2H4	M1	<1%	0.648[0.147;2.863]	5.70E-01	1872|1|0	508061|471|0	0.00046	6:31153649:G:A	244613	15
COVID19 positive hospitalized vs COVID19 negative or unknown	NFKBIL1	M1	<1%	0.362[0.010;12.546]	5.70E-01	1938|0|0	517626|106|0	0.0001	6:31153649:G:A	394045	22
COVID19 positive hospitalized vs COVID19 negative or unknown	STAP2	M1	<1%	0.647[0.146;2.879]	5.70E-01	2084|1|0	534556|408|1	0.00038	19:4719431:G:A	395299	19
COVID19 positive hospitalized vs COVID19 negative or unknown	STAP2	M3	<1%	0.647[0.146;2.879]	5.70E-01	2084|1|0	534556|408|1	0.00038	19:4719431:G:A	395299	19
COVID19 positive hospitalized vs COVID19 negative or unknown	AC018755.18	M1	<1%	1.121[0.745;1.688]	5.80E-01	2059|26|0	529089|5858|18	0.00551	19:51739497	127267	7
COVID19 positive hospitalized vs COVID19 negative or unknown	DDR1	M3	<1%	0.897[0.612;1.314]	5.80E-01	2061|24|0	528177|6786|2	0.00634	6:31153649:G:A	268430	17
COVID19 positive hospitalized vs COVID19 negative or unknown	GTF3C5	M1	<1%	1.613[0.302;8.614]	5.80E-01	2018|2|0	525364|401|0	0.00038	9:133270015:A:C	239004	17
COVID19 positive hospitalized vs COVID19 negative or unknown	IER3	M3	<1%	0.366[0.011;12.404]	5.80E-01	1940|0|0	517178|79|0	0.00009	6:31153649:G:A	409714	23
COVID19 positive hospitalized vs COVID19 negative or unknown	RPL13	M1	<1%	0.386[0.014;11.051]	5.80E-01	2020|0|0	525710|55|0	0.00005	16:89117727	443232	17
COVID19 positive hospitalized vs COVID19 negative or unknown	RPL13	M3	<1%	0.386[0.014;11.051]	5.80E-01	2020|0|0	525710|55|0	0.00005	16:89117727	443232	17
COVID19 positive hospitalized vs COVID19 negative or unknown	CXCR6	M3	<1%	1.374[0.439;4.303]	5.90E-01	2082|3|0	533961|1004|0	0.00094	3:45859597:C:T	86884	4
COVID19 positive hospitalized vs COVID19 negative or unknown	DDX39B	M1	<1%	0.369[0.010;13.799]	5.90E-01	1873|0|0	508388|144|0	0.00014	6:31153649:G:A	376784	20
COVID19 positive hospitalized vs COVID19 negative or unknown	EBI3	M3	<1%	0.659[0.147;2.957]	5.90E-01	2084|1|0	534577|387|1	0.00036	19:4719431:G:A	489881	24
COVID19 positive hospitalized vs COVID19 negative or unknown	HLA-C	M1	<1%	0.819[0.399;1.682]	5.90E-01	1932|6|0	515869|1859|4	0.0018	6:31153649:G:A	115519	8
COVID19 positive hospitalized vs COVID19 negative or unknown	HLA-C	M3	<1%	0.819[0.399;1.682]	5.90E-01	1932|6|0	515869|1859|4	0.0018	6:31153649:G:A	115519	8
COVID19 positive hospitalized vs COVID19 negative or unknown	SNAI3	M1	<1%	2.035[0.154;26.820]	5.90E-01	1937|1|0	517625|104|3	0.00011	16:89117727	439280	16
COVID19 positive hospitalized vs COVID19 negative or unknown	CYBA	M1	<1%	0.365[0.009;15.232]	6.00E-01	1873|0|0	508439|93|0	0.00009	16:89117727	474375	20
COVID19 positive hospitalized vs COVID19 negative or unknown	LTA	M3	<1%	0.370[0.009;15.194]	6.00E-01	1873|0|0	508450|82|0	0.00008	6:31153649:G:A	419093	24
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC10	M3	<1%	1.257[0.533;2.964]	6.00E-01	2080|5|0	532691|2274|0	0.00212	19:51739497	328399	23
COVID19 positive hospitalized vs COVID19 negative or unknown	ETFB	M1	<1%	0.382[0.010;15.023]	6.10E-01	2018|0|0	526137|90|0	0.00009	19:51739497	394287	29
COVID19 positive hospitalized vs COVID19 negative or unknown	IER3	M1	<1%	0.365[0.008;17.500]	6.10E-01	1873|0|0	508462|70|0	0.00007	6:31153649:G:A	409714	23
COVID19 positive hospitalized vs COVID19 negative or unknown	MAT2B	M1	<1%	0.365[0.008;17.788]	6.10E-01	1873|0|0	508463|69|0	0.00007	5:163300447	202947	4
COVID19 positive hospitalized vs COVID19 negative or unknown	RPL7A	M1	<1%	0.364[0.007;18.601]	6.10E-01	1873|0|0	508464|68|0	0.00007	9:133270015:A:C	78228	5
COVID19 positive hospitalized vs COVID19 negative or unknown	TMEM50B	M3	<1%	1.489[0.318;6.964]	6.10E-01	2004|1|0	526117|353|0	0.00033	21:33252612:A:G	198205	6
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR9	M1	<1%	0.845[0.435;1.640]	6.20E-01	2075|10|0	531749|3216|0	0.003	3:45859597:C:T	35336	2
COVID19 positive hospitalized vs COVID19 negative or unknown	PIEZO1	M3	<1%	0.954[0.793;1.149]	6.20E-01	1973|111|1	504609|30275|81	0.02844	16:89117727	402123	13
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLECL1	M1	<1%	1.211[0.569;2.576]	6.20E-01	2010|8|0	524449|1772|6	0.0017	19:51739497	475425	34
COVID19 positive hospitalized vs COVID19 negative or unknown	TMEM8C	M1	<1%	0.366[0.007;19.640]	6.20E-01	1873|0|0	508459|73|0	0.00007	9:133270015:A:C	244620	18
COVID19 positive hospitalized vs COVID19 negative or unknown	ANKRD11	M1	<1%	0.370[0.006;21.174]	6.30E-01	1873|0|0	508426|106|0	0.0001	16:89117727	150750	5
COVID19 positive hospitalized vs COVID19 negative or unknown	HLA-B	M1	<1%	0.370[0.006;21.195]	6.30E-01	1873|0|0	508450|82|0	0.00008	6:31153649:G:A	200833	11
COVID19 positive hospitalized vs COVID19 negative or unknown	HLA-B	M3	<1%	0.370[0.006;21.195]	6.30E-01	1873|0|0	508450|82|0	0.00008	6:31153649:G:A	200833	11
COVID19 positive hospitalized vs COVID19 negative or unknown	LTB	M1	<1%	0.364[0.006;22.319]	6.30E-01	1873|0|0	508475|57|0	0.00006	6:31153649:G:A	427059	27
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLECL1	M3	<1%	1.204[0.567;2.557]	6.30E-01	2077|8|0	533180|1779|6	0.00167	19:51739497	475425	34
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR1	M3	<1%	0.756[0.234;2.444]	6.40E-01	2083|2|0	534219|746|0	0.0007	21:33252612:A:G	72443	3
COVID19 positive hospitalized vs COVID19 negative or unknown	NRM	M1	<1%	1.796[0.152;21.204]	6.40E-01	1952|1|0	516825|202|0	0.0002	6:31153649:G:A	464989	33
COVID19 positive hospitalized vs COVID19 negative or unknown	GFI1B	M1	<1%	0.367[0.004;30.523]	6.60E-01	1873|0|0	508466|66|0	0.00006	9:133270015:A:C	283337	20
COVID19 positive hospitalized vs COVID19 negative or unknown	PLIN4	M1	<1%	1.140[0.639;2.033]	6.60E-01	2072|13|0	532007|2949|9	0.00277	19:4719431:G:A	214973	12
COVID19 positive hospitalized vs COVID19 negative or unknown	SON	M1	<1%	0.364[0.004;34.635]	6.60E-01	1940|0|0	517207|63|0	0.00006	21:33252612:A:G	290480	10
COVID19 positive hospitalized vs COVID19 negative or unknown	HAS1	M1	<1%	1.189[0.532;2.654]	6.70E-01	2078|7|0	533219|1745|0	0.00163	19:51739497	26071	2
COVID19 positive hospitalized vs COVID19 negative or unknown	LRG1	M1	<1%	1.270[0.427;3.778]	6.70E-01	2083|2|0	534605|360|0	0.00034	19:4719431:G:A	181492	9
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC6	M1	<1%	0.708[0.143;3.510]	6.70E-01	1872|1|0	507687|845|0	0.00083	19:51739497	219416	14
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC6	M3	<1%	0.708[0.143;3.510]	6.70E-01	1872|1|0	507687|845|0	0.00083	19:51739497	219416	14
COVID19 positive hospitalized vs COVID19 negative or unknown	TNF	M3	<1%	1.319[0.364;4.770]	6.70E-01	1950|3|0	516388|639|0	0.00062	6:31153649:G:A	422092	25
COVID19 positive hospitalized vs COVID19 negative or unknown	LST1	M1	<1%	0.366[0.003;43.447]	6.80E-01	1873|0|0	508483|49|0	0.00005	6:31153649:G:A	433650	29
COVID19 positive hospitalized vs COVID19 negative or unknown	LST1	M3	<1%	0.366[0.003;43.447]	6.80E-01	1873|0|0	508483|49|0	0.00005	6:31153649:G:A	433650	29
COVID19 positive hospitalized vs COVID19 negative or unknown	MCCD1	M1	<1%	1.676[0.149;18.821]	6.80E-01	1872|1|0	508364|168|0	0.00017	6:31153649:G:A	375365	19
COVID19 positive hospitalized vs COVID19 negative or unknown	MCCD1	M3	<1%	1.676[0.149;18.821]	6.80E-01	1872|1|0	508364|168|0	0.00017	6:31153649:G:A	375365	19
COVID19 positive hospitalized vs COVID19 negative or unknown	TNFAIP8L1	M1	<1%	0.367[0.003;43.093]	6.80E-01	1873|0|0	508485|47|0	0.00005	19:4719431:G:A	67562	3
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR1	M1	<1%	0.364[0.002;56.469]	6.90E-01	1873|0|0	508498|34|0	0.00003	3:45859597:C:T	343648	9
COVID19 positive hospitalized vs COVID19 negative or unknown	LIM2	M1	<1%	0.370[0.003;49.414]	6.90E-01	1940|0|0	517211|59|0	0.00006	19:51739497	359297	25
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF613	M3	<1%	1.380[0.280;6.797]	6.90E-01	2083|2|0	534542|423|0	0.0004	19:51739497	196723	13
COVID19 positive hospitalized vs COVID19 negative or unknown	MICA	M1	<1%	1.113[0.628;1.974]	7.10E-01	2072|13|0	531757|3199|9	0.00301	16:89117727	249983	16
COVID19 positive hospitalized vs COVID19 negative or unknown	MICA	M3	<1%	1.113[0.628;1.974]	7.10E-01	2072|13|0	531757|3199|9	0.00301	6:31153649:G:A	249983	16
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF778	M1	<1%	0.826[0.298;2.288]	7.10E-01	2082|3|0	533989|974|2	0.00091	16:89117727	103400	4
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF778	M3	<1%	0.826[0.298;2.288]	7.10E-01	2082|3|0	533989|974|2	0.00091	16:89117727	103400	4
COVID19 positive hospitalized vs COVID19 negative or unknown	FPR1	M3	<1%	0.796[0.234;2.707]	7.20E-01	2083|2|0	534362|603|0	0.00056	19:51739497	6444	1
COVID19 positive hospitalized vs COVID19 negative or unknown	PSORS1C2	M3	<1%	1.214[0.419;3.516]	7.20E-01	2016|4|0	524628|1136|1	0.00108	6:31153649:G:A	15699	4
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF613	M1	<1%	0.741[0.144;3.824]	7.20E-01	2084|1|0	534564|401|0	0.00037	19:51739497	196723	13
COVID19 positive hospitalized vs COVID19 negative or unknown	DONSON	M1	<1%	1.206[0.418;3.480]	7.30E-01	2081|4|0	534292|671|2	0.00063	21:33252612:A:G	325694	11

Comparison	Gene	Model	MAF	OR [CI]	P-value	RR	RA|AA	Freq	Variant	Pos	N
COVID19 positive hospitalized vs COVID19 negative or unknown	FSD1	M1	<1%	0.369[0.001;117.744]	7.30E-01	1873|0|0	508494|38|0	0.00004	19:4719431:G:A	414685	20
COVID19 positive hospitalized vs COVID19 negative or unknown	GBGT1	M3	<1%	1.049[0.804;1.368]	7.30E-01	2027|57|1	521986|12948|31	0.01217	9:133270015:A:C	116439	10
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC12	M1	<1%	1.182[0.460;3.036]	7.30E-01	2080|5|0	533981|982|2	0.00092	19:51739497	247857	16
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC12	M3	<1%	1.179[0.459;3.029]	7.30E-01	2080|5|0	533980|983|2	0.00092	19:51739497	247857	16
COVID19 positive hospitalized vs COVID19 negative or unknown	CDH15	M1	<1%	1.304[0.277;6.149]	7.40E-01	2083|2|0	534534|431|0	0.0004	16:89117727	54104	2
COVID19 positive hospitalized vs COVID19 negative or unknown	POU5F1	M1	<1%	0.357[0.001;166.756]	7.40E-01	1873|0|0	508507|25|0	0.00002	6:31153649:G:A	10951	2
COVID19 positive hospitalized vs COVID19 negative or unknown	FAM163B	M1	<1%	0.369[0.001;163.914]	7.50E-01	1873|0|0	508499|33|0	0.00003	9:133270015:A:C	309006	21
COVID19 positive hospitalized vs COVID19 negative or unknown	STKLD1	M1	<1%	1.166[0.455;2.987]	7.50E-01	2080|5|0	533984|980|1	0.00092	9:133270015:A:C	106458	9
COVID19 positive hospitalized vs COVID19 negative or unknown	TMEM50B	M1	<1%	0.368[0.001;185.287]	7.50E-01	1873|0|0	508494|38|0	0.00004	21:33252612:A:G	198205	6
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF350	M1	<1%	0.761[0.144;4.027]	7.50E-01	2084|1|0	534690|274|1	0.00026	19:51739497	225356	15
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF350	M3	<1%	0.761[0.144;4.027]	7.50E-01	2084|1|0	534690|274|1	0.00026	19:51739497	225356	15
COVID19 positive hospitalized vs COVID19 negative or unknown	CCDC94	M3	<1%	1.203[0.364;3.973]	7.60E-01	2083|2|0	534347|617|1	0.00058	19:4719431:G:A	472285	23
COVID19 positive hospitalized vs COVID19 negative or unknown	DPCR1	M1	<1%	0.823[0.237;2.860]	7.60E-01	2083|2|0	534233|731|1	0.00068	6:31153649:G:A	219027	12
COVID19 positive hospitalized vs COVID19 negative or unknown	DPCR1	M3	<1%	0.823[0.237;2.860]	7.60E-01	2083|2|0	534233|731|1	0.00068	6:31153649:G:A	219027	12
COVID19 positive hospitalized vs COVID19 negative or unknown	DPP9	M3	<1%	1.064[0.709;1.598]	7.60E-01	2060|25|0	528522|6430|13	0.00603	19:4719431:G:A	42868	1
COVID19 positive hospitalized vs COVID19 negative or unknown	FPR3	M1	<1%	0.369[0.001;215.142]	7.60E-01	1873|0|0	508510|22|0	0.00002	19:51739497	84251	5
COVID19 positive hospitalized vs COVID19 negative or unknown	PSORS1C1	M1	<1%	0.898[0.453;1.780]	7.60E-01	2079|6|0	533000|1964|1	0.00184	6:31153649:G:A	24017	5
COVID19 positive hospitalized vs COVID19 negative or unknown	PSORS1C1	M3	<1%	0.898[0.453;1.780]	7.60E-01	2079|6|0	533000|1964|1	0.00184	6:31153649:G:A	24017	5
COVID19 positive hospitalized vs COVID19 negative or unknown	RNF166	M1	<1%	1.273[0.270;6.009]	7.60E-01	2018|2|0	525477|288|0	0.00027	16:89117727	420160	15
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR3	M1	<1%	0.856[0.309;2.372]	7.70E-01	2017|3|0	525195|568|2	0.00054	3:45859597:C:T	404806	10
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF175	M1	<1%	0.888[0.400;1.975]	7.70E-01	2081|4|0	533617|1345|3	0.00126	19:51739497	166168	12
COVID19 positive hospitalized vs COVID19 negative or unknown	ZNF175	M3	<1%	0.888[0.400;1.975]	7.70E-01	2081|4|0	533617|1345|3	0.00126	19:51739497	166168	12
COVID19 positive hospitalized vs COVID19 negative or unknown	PABPN1L	M1	<1%	0.834[0.238;2.922]	7.80E-01	2083|2|0	534369|595|1	0.00056	16:89117727	253991	7
COVID19 positive hospitalized vs COVID19 negative or unknown	RALGDS	M1	<1%	1.232[0.274;5.532]	7.90E-01	2083|2|0	534634|331|0	0.00031	9:133270015:A:C	171429	13
COVID19 positive hospitalized vs COVID19 negative or unknown	TMEM8C	M3	<1%	0.844[0.235;3.029]	7.90E-01	2083|2|0	534301|664|0	0.00062	9:133270015:A:C	244620	18
COVID19 positive hospitalized vs COVID19 negative or unknown	UBXN6	M3	<1%	0.924[0.509;1.677]	7.90E-01	2076|8|1	532445|2517|3	0.00236	19:4719431:G:A	273934	14
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR1	M1	<1%	0.805[0.146;4.438]	8.00E-01	2019|1|0	525406|359|0	0.00034	21:33252612:A:G	72443	3
COVID19 positive hospitalized vs COVID19 negative or unknown	NRM	M3	<1%	0.850[0.238;3.033]	8.00E-01	2083|2|0	534283|682|0	0.00064	6:31153649:G:A	464989	33
COVID19 positive hospitalized vs COVID19 negative or unknown	REXO4	M3	<1%	1.097[0.527;2.285]	8.00E-01	2077|8|0	533569|1392|4	0.00131	9:133270015:A:C	136937	11
COVID19 positive hospitalized vs COVID19 negative or unknown	CACFD1	M3	<1%	0.919[0.453;1.861]	8.10E-01	2080|5|0	533381|1583|1	0.00148	9:133270015:A:C	190051	14
COVID19 positive hospitalized vs COVID19 negative or unknown	LARS2	M1	<1%	0.808[0.140;4.671]	8.10E-01	2004|3|0	526142|328|0	0.00031	3:45859597:C:T	465144	11
COVID19 positive hospitalized vs COVID19 negative or unknown	PPP1R18	M3	<1%	0.909[0.427;1.937]	8.10E-01	2079|6|0	534061|896|8	0.00085	6:31153649:G:A	476381	35
COVID19 positive hospitalized vs COVID19 negative or unknown	PPP2R1A	M1	<1%	0.366[0.000;1508.610]	8.10E-01	1873|0|0	508508|24|0	0.00002	19:51739497	450599	33
COVID19 positive hospitalized vs COVID19 negative or unknown	UHRF1	M1	<1%	0.368[0.000;1325.460]	8.10E-01	1873|0|0	508517|15|0	0.00001	19:4719431:G:A	190042	10
COVID19 positive hospitalized vs COVID19 negative or unknown	UHRF1	M3	<1%	0.368[0.000;1325.460]	8.10E-01	1873|0|0	508517|15|0	0.00001	19:4719431:G:A	190042	10
COVID19 positive hospitalized vs COVID19 negative or unknown	CDH15	M3	<1%	1.069[0.605;1.891]	8.20E-01	2072|13|0	532726|2233|6	0.0021	16:89117727	54104	2
COVID19 positive hospitalized vs COVID19 negative or unknown	MUC22	M1	<1%	0.871[0.247;3.070]	8.30E-01	1913|2|0	425252|412|9	0.00051	6:31153649:G:A	142943	9
COVID19 positive hospitalized vs COVID19 negative or unknown	MUC22	M3	<1%	0.871[0.247;3.070]	8.30E-01	1913|2|0	425252|412|9	0.00051	6:31153649:G:A	142943	9
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC10	M1	<1%	1.119[0.395;3.165]	8.30E-01	1934|4|0	515732|2000|0	0.00193	19:51739497	328399	23
COVID19 positive hospitalized vs COVID19 negative or unknown	CPNE7	M1	<1%	1.048[0.644;1.708]	8.50E-01	2067|18|0	530935|4030|0	0.00377	16:89117727	458170	18
COVID19 positive hospitalized vs COVID19 negative or unknown	LTA	M1	<1%	0.367[0.000;12959.200]	8.50E-01	1873|0|0	508522|10|0	0.00001	6:31153649:G:A	419093	24
COVID19 positive hospitalized vs COVID19 negative or unknown	RALGDS	M3	<1%	0.954[0.589;1.545]	8.50E-01	2069|16|0	530761|4198|6	0.00393	9:133270015:A:C	171429	13
COVID19 positive hospitalized vs COVID19 negative or unknown	AIF1	M3	<1%	0.852[0.143;5.082]	8.60E-01	2084|1|0	534686|279|0	0.00026	6:31153649:G:A	461680	32
COVID19 positive hospitalized vs COVID19 negative or unknown	PABPN1L	M3	<1%	0.916[0.358;2.345]	8.60E-01	2081|4|0	533859|1105|1	0.00103	16:89117727	253991	7
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC5	M3	<1%	1.036[0.692;1.549]	8.60E-01	2060|25|0	528848|6101|16	0.00573	19:51739497	127267	8
COVID19 positive hospitalized vs COVID19 negative or unknown	TNF	M3	<1%	0.368[0.000;22777.100]	8.60E-01	1873|0|0	508514|18|0	0.00002	6:31153649:G:A	422092	25
COVID19 positive hospitalized vs COVID19 negative or unknown	CACFD1	M1	<1%	1.191[0.145;9.818]	8.70E-01	2019|1|0	525594|171|0	0.00016	9:133270015:A:C	190051	14
COVID19 positive hospitalized vs COVID19 negative or unknown	CLDND2	M3	<1%	0.894[0.241;3.316]	8.70E-01	2083|2|0	534613|350|2	0.00033	19:51739497	372356	27
COVID19 positive hospitalized vs COVID19 negative or unknown	SH3GL1	M3	<1%	0.895[0.240;3.344]	8.70E-01	2083|2|0	534346|619|0	0.00058	19:4719431:G:A	357832	17
COVID19 positive hospitalized vs COVID19 negative or unknown	TNFAIP8L1	M1	<1%	1.190[0.143;9.890]	8.70E-01	2019|1|0	525556|209|0	0.0002	19:4719431:G:A	67562	3
COVID19 positive hospitalized vs COVID19 negative or unknown	TSC1	M1	<1%	0.912[0.307;2.703]	8.70E-01	2082|3|0	534222|743|0	0.00069	9:133270015:A:C	373781	23
COVID19 positive hospitalized vs COVID19 negative or unknown	SFTA2	M1	<1%	0.373[0.000;129089.000]	8.80E-01	1|70|0|0	109274|18|0	0.00008	6:31153649:G:A	222162	13
COVID19 positive hospitalized vs COVID19 negative or unknown	SFTA2	M3	<1%	0.373[0.000;129089.000]	8.80E-01	1|70|0|0	109274|18|0	0.00008	6:31153649:G:A	222162	13
COVID19 positive hospitalized vs COVID19 negative or unknown	MDC1	M3	<1%	0.914[0.244;3.430]	8.90E-01	2083|2|0	534403|562|0	0.00053	6:31153649:G:A	453185	31
COVID19 positive hospitalized vs COVID19 negative or unknown	VSIG10L	M1	<1%	0.959[0.522;1.761]	8.90E-01	2078|7|0	532727|2236|2	0.00209	19:51739497	406887	30
COVID19 positive hospitalized vs COVID19 negative or unknown	CCHCR1	M3	<1%	0.971[0.605;1.557]	9.00E-01	2068|17|0	530623|4332|10	0.00407	6:31153649:G:A	11058	3
COVID19 positive hospitalized vs COVID19 negative or unknown	GBGT1	M1	<1%	0.968[0.588;1.596]	9.00E-01	2071|13|1	531599|3355|11	0.00316	9:133270015:A:C	116439	10
COVID19 positive hospitalized vs COVID19 negative or unknown	TUBB	M1	<1%	0.381[0.000;1930640.000]	9.00E-01	1873|0|0	508521|11|0	0.00001	6:31153649:G:A	433143	28
COVID19 positive hospitalized vs COVID19 negative or unknown	TUBB	M3	<1%	0.381[0.000;1930640.000]	9.00E-01	1873|0|0	508521|11|0	0.00001	6:31153649:G:A	433143	28
COVID19 positive hospitalized vs COVID19 negative or unknown	MDC1	M1	<1%	0.927[0.245;3.513]	9.10E-01	2083|2|0	534414|551|0	0.00051	6:31153649:G:A	453185	31
COVID19 positive hospitalized vs COVID19 negative or unknown	NFKBIL1	M3	<1%	1.132[0.140;9.129]	9.10E-01	2084|1|0	534693|272|0	0.00025	6:31153649:G:A	394045	22
COVID19 positive hospitalized vs COVID19 negative or unknown	ADAMTS13	M1	<1%	1.076[0.256;4.523]	9.20E-01	2083|2|0	534440|525|0	0.00049	9:133270015:A:C	152428	12
COVID19 positive hospitalized vs COVID19 negative or unknown	ADAMTS13	M3	<1%	1.076[0.256;4.523]	9.20E-01	2083|2|0	534440|525|0	0.00049	9:133270015:A:C	152428	12
COVID19 positive hospitalized vs COVID19 negative or unknown	CBFA2T3	M3	<1%	1.028[0.613;1.725]	9.20E-01	2070|15|0	530741|4223|1	0.00395	16:89117727	240752	6
COVID19 positive hospitalized vs COVID19 negative or unknown	FSD1	M3	<1%	0.945[0.314;2.841]	9.20E-01	2082|3|0	534131|834|0	0.00078	19:4719431:G:A	414685	20
COVID19 positive hospitalized vs COVID19 negative or unknown	SIGLEC5	M1	<1%	1.022[0.680;1.537]	9.20E-01	2061|24|0	529067|5882|16	0.00553	19:51739497	127267	8
COVID19 positive hospitalized vs COVID19 negative or unknown	CLDND2	M1	<1%	1.105[0.137;8.938]	9.30E-01	1937|1|0	517548|183|1	0.00018	19:51739497	372356	27
COVID19 positive hospitalized vs COVID19 negative or unknown	IL10RB	M3	<1%	0.923[0.141;6.047]	9.30E-01	2017|1|0	525901|326|0	0.00031	21:33252612:A:G	13853	2
COVID19 positive hospitalized vs COVID19 negative or unknown	BAG6	M1	<1%	1.057[0.137;8.174]	9.60E-01	2004|1|0	526193|274|3	0.00027	6:31153649:G:A	485481	36
COVID19 positive hospitalized vs COVID19 negative or unknown	STKLD1	M3	<1%	1.016[0.526;1.960]	9.60E-01	2076|9|0	533250|1713|2	0.00161	9:133270015:A:C	106458	9
COVID19 positive hospitalized vs COVID19 negative or unknown	CCHCR1	M1	<1%	0.991[0.597;1.647]	9.70E-01	2070|15|0	531208|3748|9	0.00352	6:31153649:G:A	11058	3
COVID19 positive hospitalized vs COVID19 negative or unknown	NUDCD2	M1	<1%	1.039[0.135;8.008]	9.70E-01	2084|1|0	534749|216|0	0.0002	5:163300447	153519	2
COVID19 positive hospitalized vs COVID19 negative or unknown	SPG7	M3	<1%	1.004[0.786;1.283]	9.70E-01	2025|60|0	519685|15227|53	0.01433	16:89117727	390690	12
COVID19 positive hospitalized vs COVID19 negative or unknown	CDSN	M1	<1%	0.986[0.235;4.140]	9.80E-01	2076|9|0	532683|2282|0	0.00213	6:31153649:G:A	37625	6
COVID19 positive hospitalized vs COVID19 negative or unknown	KDM4B	M1	<1%	0.972[0.142;6.666]	9.80E-01	1939|1|0	516645|625|0	0.0006	19:4719431:G:A	313459	15
COVID19 positive hospitalized vs COVID19 negative or unknown	NKG7	M1	<1%	0.977[0.140;6.842]	9.80E-01	1872|1|0	508276|256|0	0.00025	19:51739497	367721	26
COVID19 positive hospitalized vs COVID19 negative or unknown	SNAI3	M3	<1%	1.005[0.682;1.480]	9.80E-01	2062|23|0	528564|6389|12	0.00599	16:89117727	439280	16
COVID19 positive hospitalized vs COVID19 negative or unknown	VSIG10L	M3	<1%	1.004[0.723;1.393]	9.80E-01	2047|38|0	524592|10351|22	0.00971	19:51739497	406887	30
COVID19 positive hospitalized vs COVID19 negative or unknown	LRG1	M3	<1%	0.989[0.143;6.860]	9.80E-01	2084|1|0	525547|218|0	0.00051	19:4719431:G:A	181492	9
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR1	M3	<1%	1.001[0.234;4.283]	1.00E+00	2084|1|0	534421|543|1	0.00051	3:45859597:C:T	343648	9

* RR: individuals who have genotype Reference/Reference for all variants included in burden test. RA: individuals who have genotype Reference/Alternate for at least one variant. AA: individuals who have genotype Alternate/Alternate for at least one variant.

Supplementary Table 9. Results from burden association tests for 14 genes related to interferon signaling.

Trait	Gene	Burden test	MAF	Odds Ratio [95% CI]	P-value	N cases with RR|RA|AA genotype*	N controls with RR|RA|AA genotype*	AAF
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR1	M1	<0.1%	0.8 (0.15, 4.44)	0.8033	2019|1|0	525406|359|0	3.41E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR2	M1	<0.1%	2.08 (0.62, 6.96)	0.2361	2082|3|0	534277|688|0	6.43E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IKBKG	M1	<0.1%	0.49 (0.01, 50.22)	0.7634	1873|0|0	508491|31|10	5.00E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF3	M1	<0.1%	0.96 (0.25, 3.64)	0.9476	2083|2|0	534559|406|0	3.80E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF7	M1	<0.1%	1.16 (0.43, 3.18)	0.766	2082|3|0	534124|841|0	7.86E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF9	M1	<0.1%	0.37 (0.0, 53.77)	0.696	1873|0|0	508479|53|0	5.19E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	STAT1	M1	<0.1%	0.37 (0.0, 126.71)	0.7357	1873|0|0	508490|42|0	4.11E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	STAT2	M1	<0.1%	0.35 (0.03, 4.44)	0.4215	1873|0|0	508405|127|0	1.24E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	TBK1	M1	<0.1%	0.37 (0.01, 11.96)	0.5714	1873|0|0	508445|87|0	8.52E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	TICAM1	M1	<0.1%	3.73 (0.19, 73.61)	0.387	1872|1|0	508368|164|0	1.62E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	TLR3	M1	<0.1%	1.13 (0.14, 8.83)	0.909	2084|1|0	534674|291|0	2.72E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	TLR7	M1	<0.1%	7.63 (1.87, 31.08)	0.004584	1872|0|1	508503|25|4	3.43E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	TRAF3	M1	<0.1%	0.37 (0.0, 733.64)	0.7966	1873|0|0	508504|28|0	2.74E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	UNC93B1	M1	<0.1%	1.3 (0.27, 6.24)	0.741	1938|2|0	516861|409|0	3.96E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR1	M1	<1%	0.8 (0.15, 4.44)	0.8033	2019|1|0	525406|359|0	3.41E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR2	M1	<1%	2.08 (0.62, 6.96)	0.2361	2082|3|0	534277|688|0	6.43E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IKBKG	M1	<1%	0.49 (0.01, 50.22)	0.7634	1873|0|0	508491|31|10	5.00E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF3	M1	<1%	1.82 (0.54, 6.13)	0.3334	2082|2|1	534509|455|1	4.29E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF7	M1	<1%	1.16 (0.43, 3.18)	0.766	2082|3|0	534124|841|0	7.86E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF9	M1	<1%	0.37 (0.0, 53.77)	0.696	1873|0|0	508479|53|0	5.19E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	STAT1	M1	<1%	0.37 (0.0, 126.71)	0.7357	1873|0|0	508490|42|0	4.11E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	STAT2	M1	<1%	0.35 (0.03, 4.44)	0.4215	1873|0|0	508405|127|0	1.24E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	TBK1	M1	<1%	0.37 (0.01, 11.96)	0.5714	1873|0|0	508445|87|0	8.52E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	TICAM1	M1	<1%	3.73 (0.19, 73.61)	0.387	1872|1|0	508368|164|0	1.62E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	TLR3	M1	<1%	1.13 (0.14, 8.83)	0.909	2084|1|0	534674|291|0	2.72E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	TLR7	M1	<1%	7.63 (1.87, 31.08)	0.004584	1872|0|1	508503|25|4	3.43E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	TRAF3	M1	<1%	0.37 (0.0, 733.64)	0.7966	1873|0|0	508504|28|0	2.74E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	UNC93B1	M1	<1%	1.3 (0.27, 6.24)	0.741	1938|2|0	516861|409|0	3.96E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR1	M1	singleton	0.37 (0.0, 44.0)	0.6857	1873|0|0	508477|55|0	5.39E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR2	M1	singleton	0.36 (0.0, 179.42)	0.7463	1873|0|0	508500|32|0	3.13E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	IKBKG	M1	singleton	0.55 (0.0, 2706.13)	0.8906	1873|0|0	508523|7|2	1.08E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF3	M1	singleton	0.37 (0.0, 113.18)	0.7313	1873|0|0	508495|37|0	3.62E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF7	M1	singleton	0.37 (0.0, 64.55)	0.7071	1873|0|0	508481|51|0	5.00E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF9	M1	singleton	0.37 (0.0, 249.69)	0.7666	1873|0|0	508505|27|0	2.64E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	STAT1	M1	singleton	0.37 (0.0, 301.54)	0.7688	1873|0|0	508502|30|0	2.94E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	STAT2	M1	singleton	0.37 (0.0, 37.61)	0.6705	1873|0|0	508487|45|0	4.41E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	TBK1	M1	singleton	0.36 (0.0, 86.69)	0.7179	1873|0|0	508501|31|0	3.04E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	TICAM1	M1	singleton	18.3 (1.71, 196.34)	0.01636	1872|1|0	508489|43|0	4.31E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	TLR3	M1	singleton	15.34 (1.46, 161.33)	0.02294	1939|1|0	517242|28|0	2.79E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	TLR7	M1	singleton	12.49 (2.71, 57.56)	0.001198	1872|0|1	508520|10|2	1.57E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	TRAF3	M1	singleton	0.37 (0.0, 8930.06)	0.8463	1873|0|0	508514|18|0	1.76E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	UNC93B1	M1	singleton	0.37 (0.0, 186.54)	0.7539	1873|0|0	508489|43|0	4.21E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR1	M3	<0.1%	0.76 (0.23, 2.44)	0.64	2083|2|0	534219|746|0	6.96E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNAR2	M3	<0.1%	1.97 (0.6, 6.47)	0.2651	2082|3|0	534253|712|0	6.66E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IKBKG	M3	<0.1%	0.45 (0.01, 19.74)	0.6761	1873|0|0	508452|70|10	8.82E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF3	M3	<0.1%	0.79 (0.24, 2.59)	0.692	2083|2|0	534413|552|0	5.16E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF7	M3	<0.1%	1.14 (0.52, 2.49)	0.7481	2080|5|0	533486|1479|0	1.38E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	IRF9	M3	<0.1%	0.37 (0.0, 53.77)	0.696	1873|0|0	508479|53|0	5.19E-05

COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT1*	M3	<0.1%	0.37 (0.04, 3.49)	0.3816	2018|0|0	526009|218|0	2.06E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT2*	M3	<0.1%	2.6 (1.27, 5.31)	0.008795	2073|12|0	533405|1559|1	1.46E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TBK1*	M3	<0.1%	1.11 (0.45, 2.79)	0.8171	2081|4|0	533861|1103|1	1.03E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M3	<0.1%	3.66 (0.19, 71.22)	0.392	1872|1|0	508365|167|0	1.65E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR3*	M3	<0.1%	0.81 (0.43, 1.49)	0.4921	2077|8|0	532355|2609|1	2.44E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR7*	M3	<0.1%	1.58 (0.63, 3.98)	0.3321	2001|3|1	525830|477|163	7.64E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAF3*	M3	<0.1%	3.01 (0.53, 17.22)	0.2148	2019|1|0	525523|242|0	2.30E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*UNC93B1*	M3	<0.1%	1.66 (0.77, 3.58)	0.1922	2075|10|0	533331|1634|0	1.53E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M3	<1%	0.76 (0.23, 2.44)	0.64	2083|2|0	534219|746|0	6.96E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M3	<1%	1.97 (0.6, 6.47)	0.2651	2082|3|0	534253|712|0	6.66E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IKBKG*	M3	<1%	1.04 (0.54, 2.01)	0.9101	1935|0|3	516444|949|339	1.57E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF3*	M3	<1%	1.38 (0.46, 4.15)	0.5704	2082|2|1	534363|601|1	5.65E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF7*	M3	<1%	1.14 (0.52, 2.49)	0.7481	2080|5|0	533486|1479|0	1.38E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF9*	M3	<1%	0.37 (0.0, 53.77)	0.696	1873|0|0	508479|53|0	5.19E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT1*	M3	<1%	0.37 (0.04, 3.49)	0.3816	2018|0|0	526009|218|0	2.06E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT2*	M3	<1%	2.6 (1.27, 5.31)	0.008795	2073|12|0	533405|1559|1	1.46E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TBK1*	M3	<1%	1.11 (0.45, 2.79)	0.8171	2081|4|0	533861|1103|1	1.03E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M3	<1%	3.66 (0.19, 71.22)	0.392	1872|1|0	508365|167|0	1.65E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR3*	M3	<1%	0.83 (0.52, 1.32)	0.4285	2070|15|0	530068|4895|2	4.57E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR7*	M3	<1%	1.58 (0.63, 3.98)	0.3321	2001|3|1	525830|477|163	7.64E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAF3*	M3	<1%	0.89 (0.48, 1.65)	0.711	2076|9|0	532255|2706|4	2.54E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*UNC93B1*	M3	<1%	1.66 (0.77, 3.58)	0.1922	2075|10|0	533331|1634|0	1.53E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M3	singleton	0.37 (0.01, 20.63)	0.6273	1873|0|0	508465|67|0	6.56E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M3	singleton	0.36 (0.0, 138.92)	0.7352	1873|0|0	508498|34|0	3.33E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IKBKG*	M3	singleton	0.55 (0.0, 2553.85)	0.889	1873|0|0	508522|8|2	1.18E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF3*	M3	singleton	0.37 (0.0, 46.47)	0.687	1940|0|0	517212|58|0	5.59E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF7*	M3	singleton	2.94 (0.17, 51.0)	0.4591	2004|1|0	526371|99|0	9.46E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF9*	M3	singleton	0.37 (0.0, 249.69)	0.7666	1873|0|0	508505|27|0	2.64E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT1*	M3	singleton	0.37 (0.01, 19.67)	0.6207	1873|0|0	508458|74|0	7.25E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT2*	M3	singleton	35.11 (4.02, 306.33)	0.001283	2018|2|0	525651|114|0	1.10E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TBK1*	M3	singleton	0.37 (0.02, 8.91)	0.5401	2005|0|0	526361|109|0	1.03E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M3	singleton	17.91 (1.68, 190.85)	0.01686	1872|1|0	508486|46|0	4.60E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR3*	M3	singleton	0.93 (0.14, 6.19)	0.943	2084|1|0	534786|178|1	1.69E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR7*	M3	singleton	4.02 (1.16, 13.91)	0.02818	1939|0|1	517197|55|18	8.96E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAF3*	M3	singleton	0.37 (0.01, 21.93)	0.6308	1873|0|0	508461|71|0	6.96E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*UNC93B1*	M3	singleton	0.38 (0.01, 12.45)	0.5832	1953|0|0	516939|88|0	8.48E-05
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR1*	M1	<0.1%	2.62 (0.18, 38.8)	0.4837	571|1|0	516685|342|0	3.31E-04
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR2*	M1	<0.1%	1.97 (0.17, 22.68)	0.5855	589|1|0	525553|674|0	6.41E-04
COVID19 positive severe vs COVID19 negative or unknown	*IKBKG*	M1	<0.1%	14.74 (1.12, 193.22)	0.04042	539|0|0	508491|31|10	5.01E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF3*	M1	<0.1%	3.02 (0.6, 15.18)	0.1793	589|1|0	525854|373|0	3.55E-04
COVID19 positive severe vs COVID19 negative or unknown	*IRF7*	M1	<0.1%	2.68 (0.39, 18.58)	0.3189	588|2|0	525395|832|0	7.92E-04
COVID19 positive severe vs COVID19 negative or unknown	*IRF9*	M1	<0.1%	0.42 (0.0, 5297.95)	0.8575	539|0|0	508479|53|0	5.21E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT1*	M1	<0.1%	0.38 (0.0, 3004.31)	0.8315	539|0|0	508490|42|0	4.13E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT2*	M1	<0.1%	0.37 (0.0, 38.82)	0.6778	539|0|0	508405|127|0	1.25E-04
COVID19 positive severe vs COVID19 negative or unknown	*TBK1*	M1	<0.1%	0.38 (0.0, 211.44)	0.7619	539|0|0	508445|87|0	8.54E-05
COVID19 positive severe vs COVID19 negative or unknown	*TICAM1*	M1	<0.1%	0.89 (0.05, 15.25)	0.9349	539|0|0	508368|164|0	1.61E-04
COVID19 positive severe vs COVID19 negative or unknown	*TLR3*	M1	<0.1%	0.41 (0.01, 21.61)	0.6594	590|0|0	525950|277|0	2.63E-04
COVID19 positive severe vs COVID19 negative or unknown	*TLR7*	M1	<0.1%	42.12 (0.51, 3486.63)	0.0969	539|0|0	508503|25|4	3.24E-05
COVID19 positive severe vs COVID19 negative or unknown	*TRAF3*	M1	<0.1%	0.43 (0.0, 281622.0)	0.9011	539|0|0	508504|28|0	2.75E-05
COVID19 positive severe vs COVID19 negative or unknown	*UNC93B1*	M1	<0.1%	3.35 (0.18, 61.63)	0.4157	538|1|0	508128|404|0	3.98E-04
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR1*	M1	<1%	2.62 (0.18, 38.8)	0.4837	571|1|0	516685|342|0	3.31E-04

Comparison	Gene	Model	Freq	OR (CI)	p-value	Counts	Counts	Value
COVID19 positive severe vs COVID19 negative or unknown	IFNAR2	M1	<1%	1.97 (0.17, 22.68)	0.5855	589|1|0	525553|674|0	6.41E-04
COVID19 positive severe vs COVID19 negative or unknown	IKBKG	M1	<1%	14.74 (1.12, 193.22)	0.04042	539|0|0	508491|31|10	5.01E-04
COVID19 positive severe vs COVID19 negative or unknown	IRF3	M1	<1%	3.02 (0.6, 15.18)	0.1793	589|1|0	525854|373|0	3.55E-04
COVID19 positive severe vs COVID19 negative or unknown	IRF7	M1	<1%	2.68 (0.39, 18.58)	0.3189	588|2|0	525395|832|0	7.92E-04
COVID19 positive severe vs COVID19 negative or unknown	IRF9	M1	<1%	0.42 (0.0, 5297.95)	0.8575	539|0|0	508479|53|0	5.21E-05
COVID19 positive severe vs COVID19 negative or unknown	STAT1	M1	<1%	0.38 (0.0, 3004.31)	0.8315	539|0|0	508490|42|0	4.13E-05
COVID19 positive severe vs COVID19 negative or unknown	STAT2	M1	<1%	0.37 (0.0, 38.82)	0.6778	539|0|0	508405|127|0	1.25E-04
COVID19 positive severe vs COVID19 negative or unknown	TBK1	M1	<1%	0.38 (0.0, 211.44)	0.7619	539|0|0	508445|87|0	8.54E-05
COVID19 positive severe vs COVID19 negative or unknown	TICAM1	M1	<1%	0.89 (0.05, 15.25)	0.9349	539|0|0	508368|164|0	1.61E-04
COVID19 positive severe vs COVID19 negative or unknown	TLR3	M1	<1%	0.41 (0.01, 21.61)	0.6594	590|0|0	525950|277|0	2.63E-04
COVID19 positive severe vs COVID19 negative or unknown	TLR7	M1	<1%	42.12 (0.51, 3486.63)	0.0969	539|0|0	508503|25|4	3.24E-05
COVID19 positive severe vs COVID19 negative or unknown	TRAF3	M1	<1%	0.43 (0.0, 281622.0)	0.9011	539|0|0	508504|28|0	2.75E-05
COVID19 positive severe vs COVID19 negative or unknown	UNC93B1	M1	<1%	3.35 (0.18, 61.63)	0.4157	538|1|0	508128|404|0	3.98E-04
COVID19 positive severe vs COVID19 negative or unknown	IFNAR1	M1	singleton	0.37 (0.0, 165.53)	0.7518	539|0|0	508477|55|0	5.40E-05
COVID19 positive severe vs COVID19 negative or unknown	IFNAR2	M1	singleton	0.48 (0.0, 901579.0)	0.9216	539|0|0	508500|32|0	3.14E-05
COVID19 positive severe vs COVID19 negative or unknown	IKBKG	M1	singleton	0.58 (0.0, 711727.0)	0.939	490|0|0	399233|6|1	1.00E-05
COVID19 positive severe vs COVID19 negative or unknown	IRF3	M1	singleton	24.01 (0.35, 1669.95)	0.1419	539|0|0	508495|37|0	3.63E-05
COVID19 positive severe vs COVID19 negative or unknown	IRF7	M1	singleton	0.45 (0.0, 19828.4)	0.8843	539|0|0	508481|51|0	5.01E-05
COVID19 positive severe vs COVID19 negative or unknown	IRF9	M1	singleton	0.45 (0.0, 564343.0)	0.9115	539|0|0	508505|27|0	2.65E-05
COVID19 positive severe vs COVID19 negative or unknown	STAT1	M1	singleton	0.38 (0.0, 9818.87)	0.8505	539|0|0	508502|30|0	2.95E-05
COVID19 positive severe vs COVID19 negative or unknown	STAT2	M1	singleton	0.39 (0.0, 13826.4)	0.861	539|0|0	508487|45|0	4.42E-05
COVID19 positive severe vs COVID19 negative or unknown	TBK1	M1	singleton	0.38 (0.0, 28255.6)	0.8649	539|0|0	508501|31|0	3.04E-05
COVID19 positive severe vs COVID19 negative or unknown	TICAM1	M1	singleton	15.49 (0.28, 860.18)	0.1812	539|0|0	508489|43|0	4.22E-05
COVID19 positive severe vs COVID19 negative or unknown	TLR3	M1	singleton	0.38 (0.0, 18335.2)	0.8602	539|0|0	508509|23|0	2.26E-05
COVID19 positive severe vs COVID19 negative or unknown	TLR7	M1	singleton	0.4 (0.0, 3891300000.0)	0.9371	490|0|0	399229|9|2	1.63E-05
COVID19 positive severe vs COVID19 negative or unknown	TRAF3	M1	singleton	0.42 (0.0, 1871470.0)	0.9114	539|0|0	508514|18|0	1.77E-05
COVID19 positive severe vs COVID19 negative or unknown	UNC93B1	M1	singleton	0.42 (0.0, 20393.0)	0.8758	539|0|0	508489|43|0	4.22E-05
COVID19 positive severe vs COVID19 negative or unknown	IFNAR1	M3	<0.1%	1.07 (0.15, 7.68)	0.9458	589|1|0	525500|727|0	6.91E-04
COVID19 positive severe vs COVID19 negative or unknown	IFNAR2	M3	<0.1%	1.88 (0.17, 20.82)	0.6068	589|1|0	525529|698|0	6.63E-04
COVID19 positive severe vs COVID19 negative or unknown	IKBKG	M3	<0.1%	12.55 (0.99, 159.28)	0.051	539|0|0	508452|70|10	8.84E-05
COVID19 positive severe vs COVID19 negative or unknown	IRF3	M3	<0.1%	2.53 (0.54, 11.8)	0.2388	589|1|0	525713|514|0	4.89E-04
COVID19 positive severe vs COVID19 negative or unknown	IRF7	M3	<0.1%	3.07 (0.81, 11.64)	0.09817	587|3|0	524764|1463|0	1.39E-03
COVID19 positive severe vs COVID19 negative or unknown	IRF9	M3	<0.1%	0.42 (0.0, 5297.95)	0.8575	539|0|0	508479|53|0	5.21E-05
COVID19 positive severe vs COVID19 negative or unknown	STAT1	M3	<0.1%	0.38 (0.01, 14.6)	0.6027	590|0|0	526009|218|0	2.07E-04
COVID19 positive severe vs COVID19 negative or unknown	STAT2	M3	<0.1%	1.64 (0.36, 7.55)	0.5246	587|3|0	524718|1508|1	1.44E-03
COVID19 positive severe vs COVID19 negative or unknown	TBK1	M3	<0.1%	1.96 (0.33, 11.47)	0.456	588|2|0	525137|1089|1	1.04E-03
COVID19 positive severe vs COVID19 negative or unknown	TICAM1	M3	<0.1%	0.89 (0.05, 15.22)	0.9349	539|0|0	508365|167|0	1.64E-04
COVID19 positive severe vs COVID19 negative or unknown	TLR3	M3	<0.1%	0.74 (0.24, 2.26)	0.5951	588|2|0	523680|2546|1	2.42E-03
COVID19 positive severe vs COVID19 negative or unknown	TLR7	M3	<0.1%	1.22 (0.29, 5.15)	0.7855	557|0|0	517105|467|160	7.59E-04
COVID19 positive severe vs COVID19 negative or unknown	TRAF3	M3	<0.1%	14.61 (1.54, 138.27)	0.01935	571|1|0	516792|235|0	2.28E-04
COVID19 positive severe vs COVID19 negative or unknown	UNC93B1	M3	<0.1%	3.13 (1.26, 7.77)	0.01414	584|6|0	524612|1615|0	1.54E-03
COVID19 positive severe vs COVID19 negative or unknown	IFNAR1	M3	<1%	1.07 (0.15, 7.68)	0.9458	589|1|0	525500|727|0	6.91E-04
COVID19 positive severe vs COVID19 negative or unknown	IFNAR2	M3	<1%	1.88 (0.17, 20.82)	0.6068	589|1|0	525529|698|0	6.63E-04
COVID19 positive severe vs COVID19 negative or unknown	IKBKG	M3	<1%	1.41 (0.48, 4.17)	0.5303	556|0|1	516444|949|339	1.57E-03
COVID19 positive severe vs COVID19 negative or unknown	IRF3	M3	<1%	2.53 (0.54, 11.8)	0.2388	589|1|0	525713|514|0	4.89E-04
COVID19 positive severe vs COVID19 negative or unknown	IRF7	M3	<1%	3.07 (0.81, 11.64)	0.09817	587|3|0	524764|1463|0	1.39E-03
COVID19 positive severe vs COVID19 negative or unknown	IRF9	M3	<1%	0.42 (0.0, 5297.95)	0.8575	539|0|0	508479|53|0	5.21E-05
COVID19 positive severe vs COVID19 negative or unknown	STAT1	M3	<1%	0.38 (0.01, 14.6)	0.6027	590|0|0	526009|218|0	2.07E-04
COVID19 positive severe vs COVID19 negative or unknown	STAT2	M3	<1%	1.64 (0.36, 7.55)	0.5246	587|3|0	524718|1508|1	1.44E-03
COVID19 positive severe vs COVID19 negative or unknown	TBK1	M3	<1%	1.96 (0.33, 11.47)	0.456	588|2|0	525137|1089|1	1.04E-03
COVID19 positive severe vs COVID19 negative or unknown	TICAM1	M3	<1%	0.89 (0.05, 15.22)	0.9349	539|0|0	508365|167|0	1.64E-04

					RR|RA|AA		
COVID19 positive severe vs COVID19 negative or unknown	*TLR3*	M3	<1%	0.97 (0.41, 2.26)	0.9396	585|5|0	521403|4822|2	4.59E-03
COVID19 positive severe vs COVID19 negative or unknown	*TLR7*	M3	<1%	1.22 (0.29, 5.15)	0.7855	557|0|0	517105|467|160	7.59E-04
COVID19 positive severe vs COVID19 negative or unknown	*TRAF3*	M3	<1%	1.27 (0.49, 3.25)	0.6217	587|3|0	523530|2693|4	2.57E-03
COVID19 positive severe vs COVID19 negative or unknown	*UNC93B1*	M3	<1%	3.13 (1.26, 7.77)	0.01414	584|6|0	524612|1615|0	1.54E-03
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR1*	M3	singleton	0.37 (0.0, 119.72)	0.738	539|0|0	508465|67|0	6.58E-05
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR2*	M3	singleton	0.47 (0.0, 448932.0)	0.9144	539|0|0	508498|34|0	3.34E-05
COVID19 positive severe vs COVID19 negative or unknown	*IKBKG*	M3	singleton	0.57 (0.0, 614503.0)	0.9374	490|0|0	399232|7|1	1.13E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF3*	M3	singleton	20.95 (0.32, 1352.58)	0.1525	539|0|0	508480|52|0	5.11E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF7*	M3	singleton	0.42 (0.0, 600.62)	0.8166	557|0|0	517640|92|0	8.88E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF9*	M3	singleton	0.45 (0.0, 564343.0)	0.9115	539|0|0	508505|27|0	2.65E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT1*	M3	singleton	0.38 (0.0, 269.14)	0.7735	539|0|0	508458|74|0	7.27E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT2*	M3	singleton	0.4 (0.0, 128.93)	0.7543	572|0|0	516919|108|0	1.04E-04
COVID19 positive severe vs COVID19 negative or unknown	*TBK1*	M3	singleton	0.38 (0.0, 184.6)	0.7614	557|0|0	517628|104|0	1.00E-04
COVID19 positive severe vs COVID19 negative or unknown	*TICAM1*	M3	singleton	15.0 (0.27, 819.65)	0.1846	539|0|0	508486|46|0	4.52E-05
COVID19 positive severe vs COVID19 negative or unknown	*TLR3*	M3	singleton	0.41 (0.01, 15.67)	0.6287	590|0|0	526065|161|1	1.55E-04
COVID19 positive severe vs COVID19 negative or unknown	*TLR7*	M3	singleton	11.63 (0.84, 161.65)	0.06761	539|0|0	508468|49|15	7.76E-05
COVID19 positive severe vs COVID19 negative or unknown	*TRAF3*	M3	singleton	0.4 (0.0, 689.93)	0.8098	539|0|0	508461|71|0	6.97E-05
COVID19 positive severe vs COVID19 negative or unknown	*UNC93B1*	M3	singleton	0.42 (0.0, 250.75)	0.7916	572|0|0	516939|88|0	8.50E-05

* RR: individuals who have genotype Reference/Reference for all variants included in burden test. RA: individuals who have genotype Reference/Alternate for at least one variant. AA: individuals who have genotype Alternate/Alternate for at least one variant.

Supplementary Table 10. Results from burden association tests for 32 additional genes of biological or therapeutic interest.

Trait	Gene	Burden test	MAF	Odds Ratio [95% CI]	P-value	N cases with RR|RA|AA genotype*	N controls with RR|RA|AA genotype*	AAF
COVID19 positive hospitalized vs COVID19 negative or unknown	IL23R	M1	<1%	3.849[0.853;17.373]	8.00E-02	1871|2|0	508324|208|0	0.00021
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1A	M3	<1%	2.350[0.835;6.611]	1.10E-01	2016|4|0	525349|415|1	0.0004
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL3	M1	<1%	14.959[0.345;647.891]	1.60E-01	1872|1|0	508438|94|0	0.00009
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1A	M1	<1%	4.218[0.574;31.008]	1.60E-01	2019|1|0	525641|124|0	0.00012
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL1	M3	<1%	0.369[0.086;1.585]	1.80E-01	2085|0|0	534569|395|1	0.00037
COVID19 positive hospitalized vs COVID19 negative or unknown	TMPRSS2	M1	<1%	2.526[0.646;9.876]	1.80E-01	1936|4|0	516764|506|0	0.00049
COVID19 positive hospitalized vs COVID19 negative or unknown	C5	M1	<1%	2.077[0.702;6.144]	1.90E-01	2081|4|0	534324|640|1	0.0006
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL1	M1	<1%	0.369[0.081;1.687]	2.00E-01	2085|0|0	534607|357|1	0.00033
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17RC	M3	<1%	1.643[0.749;3.604]	2.20E-01	2080|5|0	533824|1140|1	0.00107
COVID19 positive hospitalized vs COVID19 negative or unknown	VEGFA	M3	<1%	0.558[0.219;1.418]	2.20E-01	2083|2|0	533873|1091|1	0.00102
COVID19 positive hospitalized vs COVID19 negative or unknown	IL7R	M1	<1%	1.668[0.692;4.019]	2.50E-01	2079|6|0	533848|1117|0	0.00105
COVID19 positive hospitalized vs COVID19 negative or unknown	IL12B	M3	<1%	2.200[0.438;11.048]	3.40E-02	2017|1|0	526033|194|0	0.00018
COVID19 positive hospitalized vs COVID19 negative or unknown	IL23A	M3	<1%	0.366[0.046;2.919]	3.40E-01	1938|0|0	517449|282|1	0.00027
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17RA	M1	<1%	0.359[0.040;3.220]	3.60E-01	2020|0|0	525537|228|0	0.00022
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNLR1	M3	<1%	0.366[0.040;3.321]	3.70E-01	1938|0|0	517531|201|0	0.00019
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1B	M3	<1%	0.369[0.039;3.491]	3.80E-01	2005|0|0	526208|262|0	0.00025
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL3	M3	<1%	3.464[0.185;64.982]	4.10E-01	1939|1|0	517141|129|0	0.00013
COVID19 positive hospitalized vs COVID19 negative or unknown	JAK1	M1	<1%	1.942[0.398;9.474]	4.10E-01	1937|1|0	517541|189|2	0.00019
COVID19 positive hospitalized vs COVID19 negative or unknown	JAK1	M3	<1%	1.942[0.398;9.474]	4.10E-01	1937|1|0	517541|189|2	0.00019
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNLR1	M1	<1%	0.365[0.030;4.527]	4.30E-01	1938|0|0	517571|161|0	0.00015
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1B	M1	<1%	0.368[0.030;4.481]	4.30E-01	1873|0|0	508320|212|0	0.00021
COVID19 positive hospitalized vs COVID19 negative or unknown	JAK2	M1	<1%	0.366[0.029;4.555]	4.30E-01	1938|0|0	517530|202|0	0.00019
COVID19 positive hospitalized vs COVID19 negative or unknown	IL23R	M3	<1%	0.847[0.554;1.296]	4.40E-01	2067|18|0	529085|5861|19	0.00551
COVID19 positive hospitalized vs COVID19 negative or unknown	VEGFA	M1	<1%	0.661[0.218;2.002]	4.60E-01	2083|2|0	534217|747|1	0.0007
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1R1	M1	<1%	0.666[0.222;1.995]	4.70E-01	1936|2|0	517281|444|7	0.00044
COVID19 positive hospitalized vs COVID19 negative or unknown	IL7R	M3	<1%	1.269[0.666;2.419]	4.70E-01	2075|10|0	532768|2197|0	0.00205
COVID19 positive hospitalized vs COVID19 negative or unknown	TMPRSS2	M3	<1%	1.341[0.606;2.967]	4.70E-01	2077|8|0	533498|1467|0	0.00137
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNG	M3	<1%	0.366[0.020;6.537]	4.90E-01	1873|0|0	508402|130|0	0.00013
COVID19 positive hospitalized vs COVID19 negative or unknown	BTK	M3	<1%	0.497[0.061;4.077]	5.10E-01	2020|0|0	525622|114|29	0.00016
COVID19 positive hospitalized vs COVID19 negative or unknown	IL6	M3	<1%	0.369[0.019;7.067]	5.10E-01	1953|0|0	516905|122|0	0.00012
COVID19 positive hospitalized vs COVID19 negative or unknown	IL6R	M1	<1%	0.377[0.020;7.210]	5.20E-01	1940|0|0	517152|118|0	0.00011
COVID19 positive hospitalized vs COVID19 negative or unknown	IL12B	M1	<1%	0.365[0.016;8.562]	5.30E-01	1873|0|0	508442|90|0	0.00009
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1R1	M3	<1%	0.739[0.283;1.931]	5.40E-01	2082|3|0	534274|684|7	0.00065
COVID19 positive hospitalized vs COVID19 negative or unknown	IL6	M1	<1%	0.367[0.014;9.615]	5.50E-01	1873|0|0	508423|109|0	0.00011
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNGR1	M3	<1%	0.651[0.149;2.841]	5.70E-01	2084|1|0	534532|433|0	0.0004
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL2	M3	<1%	1.481[0.380;5.766]	5.70E-01	2082|3|0	534408|557|0	0.00052
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNB1	M3	<1%	0.828[0.423;1.623]	5.80E-01	2011|7|0	524038|2186|3	0.00208
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNG	M1	<1%	0.364[0.011;12.464]	5.80E-01	1873|0|0	508453|79|0	0.00008
COVID19 positive hospitalized vs COVID19 negative or unknown	JAK2	M3	<1%	0.850[0.481;1.503]	5.80E-01	2075|10|0	532245|2714|6	0.00255
COVID19 positive hospitalized vs COVID19 negative or unknown	IL4R	M1	<1%	1.931[0.154;24.219]	6.10E-01	1937|1|0	517553|179|0	0.00017
COVID19 positive hospitalized vs COVID19 negative or unknown	PDCD1	M3	<1%	0.367[0.005;29.373]	6.50E-01	1873|0|0	508473|59|0	0.00006
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17A	M1	<1%	0.364[0.004;35.613]	6.70E-01	1873|0|0	508492|40|0	0.00004
COVID19 positive hospitalized vs COVID19 negative or unknown	IL23A	M1	<1%	0.365[0.002;57.511]	7.00E-01	1873|0|0	508494|38|0	0.00004
COVID19 positive hospitalized vs COVID19 negative or unknown	ACE2	M1	<1%	0.392[0.002;61.868]	7.20E-01	1873|0|0	508485|44|3	0.00005
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1RAP	M3	<1%	1.272[0.349;4.641]	7.20E-01	2083|2|0	534386|579|0	0.00054
COVID19 positive hospitalized vs COVID19 negative or unknown	IL4R	M3	<1%	1.534[0.147;16.057]	7.20E-01	2017|1|0	526039|188|0	0.00018
COVID19 positive hospitalized vs COVID19 negative or unknown	PDCD1	M1	<1%	0.367[0.002;83.673]	7.20E-01	1873|0|0	508492|40|0	0.00004
COVID19 positive hospitalized vs COVID19 negative or unknown	CSF2	M3	<1%	0.368[0.001;136.635]	7.40E-01	1873|0|0	508491|41|0	0.00004
COVID19 positive hospitalized vs COVID19 negative or unknown	BTK	M1	<1%	0.363[0.001;230.098]	7.60E-01	1873|0|0	508505|27|0	0.00003
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNGR1	M1	<1%	0.807[0.145;4.481]	8.10E-01	2084|1|0	534629|336|0	0.00031

COVID19 positive hospitalized vs COVID19 negative or unknown	ACE2	M3	<1%	0.944[0.582;1.533]	8.20E-01	2079|2|4	532861|1626|478	0.00241
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR5	M1	<1%	0.939[0.521;1.690]	8.30E-01	2077|8|0	532508|2453|4	0.0023
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR5	M3	<1%	0.939[0.521;1.690]	8.30E-01	2077|8|0	532508|2453|4	0.0023
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1RAP	M1	<1%	1.281[0.142;11.540]	8.30E-01	1872|1|0	508333|199|0	0.0002
COVID19 positive hospitalized vs COVID19 negative or unknown	CSF2	M1	<1%	0.370[0.000;6631.170]	8.40E-01	1873|0|0	508515|17|0	0.00002
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17RC	M1	<1%	1.113[0.317;3.899]	8.70E-01	2083|2|0	534378|587|0	0.00055
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17A	M3	<1%	0.885[0.140;5.608]	9.00E-01	1872|1|0	508249|283|0	0.00028
COVID19 positive hospitalized vs COVID19 negative or unknown	C5	M3	<1%	0.984[0.670;1.445]	9.30E-01	2059|26|0	529016|5928|21	0.00558
COVID19 positive hospitalized vs COVID19 negative or unknown	IL6R	M3	<1%	1.089[0.143;8.291]	9.30E-01	2084|1|0	534746|219|0	0.0002
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17RA	M3	<1%	1.009[0.713;1.429]	9.60E-01	2052|33|0	527528|7417|20	0.00697
COVID19 positive hospitalized vs COVID19 negative or unknown	IL33	M3	<1%	0.988[0.649;1.505]	9.60E-01	2063|22|0	529239|5720|6	0.00536
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNB1	M1	<1%	0.987[0.470;2.070]	9.70E-01	1946|7|0	515284|1741|2	0.00169
COVID19 positive hospitalized vs COVID19 negative or unknown	IL33	M1	<1%	0.993[0.652;1.513]	9.70E-01	2063|22|0	529265|5694|6	0.00533
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL2	M1	<1%	0.992[0.240;4.100]	9.90E-01	2083|2|0	534469|496|0	0.00046

* RR: individuals who have genotype Reference/Reference for all variants included in burden test. RA: individuals who have genotype Reference/Alternate for at least one variant. AA: individuals who have genotype Alternate/Alternate for at least one variant.